


A Diversity-Oriented Strategy for Chemical Synthesis Glycosphingolipids: Synthesis of Glycosphingolipid LcGg4 and Its Analogs and Derivatives

Rajendra S. Rohokale, Qingjiang Li, and Zhongwu Guo*

*Department of Chemistry, University of Florida, 214 Leigh Hall, Gainesville, Florida 32611,
United States*

* Corresponding author Email: zguo@chem.ufl.edu

TOC Graphic:



Abstract: A diversity-oriented strategy was developed for the synthesis of glycosphingolipids (GSLs). This strategy was highlighted by using a simple lactoside containing the core structures of GSL glycan and lipid as the universal starting material to obtain different synthetic targets upon stepwise elongation of the glycan via chemical glycosylations and on-site remodeling of the lipid via chemoselective cross-metathesis and *N*-acylation. The strategy was verified with the synthesis of a lacto-ganglio GSL, LcGg4, which is a biomarker of undifferentiated malignant myeloid cells, and a series of its analogs or derivatives carrying different sugar chains and unique functionalities or molecular labels. This synthetic strategy should be widely applicable and, therefore, be utilized to rapidly access various GSLs and related derivatives by using different donors for glycosylations and different substrates for lipid remodeling following each glycosylation.

Introduction

Glycosphingolipids (GSLs) are major and essential constituents of the cell membrane and play a pivotal role in various biological and pathological processes.¹⁻⁷ For example, GSLs are involved in the modulation of signal transduction, cell recognition, proliferation and differentiation,⁸ cell-cell interaction,⁹⁻¹⁰ and other cellular functions,¹¹ as well as in the pathogenesis of many diseases such as cancer,¹²⁻¹⁴ diabetes,¹⁵ Alzheimer's disease,¹⁶⁻¹⁷ Gaucher and related disorders,¹⁸ bacterial and viral infections,¹⁹⁻²¹ etc. Structurally, GSLs are composed of a hydrophilic carbohydrate head group and a hydrophobic sphingolipid, known as ceramide, which are stitched together through a β -glycosidic bond (Figure 1). GSLs are attached to cells via insertion of their lipid tails into the cell membrane while exposing their glycans onto the cell surface. Both the glycans and the lipids of GSLs can serve as recognition motifs to interact with other molecules and implement important functions. As a result, GSLs are structurally diverse in both the glycan and the lipid.




Figure 1: The representative structure of GSL and strategies developed for GSL synthesis


To study GSLs and gain in-depth understanding of their functions, it is necessary to have access to these molecules in homogeneous and structurally defined forms. Yet, the amphiphilic property and the relatively low abundance of individual GSLs in nature make their isolation and purification from biological tissues a daunting task. Consequently, their total synthesis has become the most attractive and probably the only practical means to access not only pure natural GSLs but also their functionalized derivatives. In the past several decades, a number of GSLs have been successfully synthesized by various strategies,²²⁻²⁵ but overall, GSL synthesis remains a significant challenge.²⁶ For their chemical synthesis, in addition to conventional problems associated with oligosaccharide assembly, the ceramide moiety of GSL has brought about a series of other issues. For instance, the hydrogen bonding between the amido and the primary hydroxyl groups in ceramide and the high steric hindrance caused by its sheer size have substantially reduced the nucleophilicity of ceramide (Figure 1A), rendering its direct coupling with glycans exceptionally difficult, although this is still the most common strategy used for GSL synthesis.²²⁻²³ On the other hand, if the ceramide moiety is introduced at the very beginning of the synthesis, although the efficiency to install ceramide can be improved, subsequent glycosylation reactions for glycan elongation can be affected. To address this problem, partial ceramide structures, such as azido sphingosine or its short fragments (Figure 1B), were employed to couple with glycans and then converted into ceramide on-site, upon lipid remodelling *via* such as selective *N*-acylation, olefin metathesis²⁷ and Wittig reaction.²⁴ Kiso and co-workers²⁸⁻²⁹ also developed a glyco-ceramide cassette strategy (Figure 1C), in which ceramide was linked to a simple glycan first, which enabled intramolecular glycosylation, and the resultant glycoside was subsequently subjected to glycan elongation. Although the strategy could improve the efficiency and stereoselectivity of ceramide glycosylation, a major issue was that subsequent glycosylations suffered from significant decrease in reaction yields. For enzymatic GSL synthesis, Chen³⁰⁻³³ and others³⁴⁻⁴¹ have demonstrated that elongating glycans through glycosyltransferase-catalysed glycosylations was efficient, whilst a major problem was related to the ceramide moiety as well. Its presence can have an impact on substrate solubility in aqueous solution, whereas late-stage installation and/or on-site construction of the ceramide moiety using complex free glycans can be challenging. To address this problem, the Withers group⁴²⁻⁴⁵ developed an elegant enzymatic methodology for on-site ceramide assembly using engineered endoglycoceramidase and ceramide *N*-deacylase to catalyse sphingosine attachment to glycans and then acyl group attachment to the sphingosine amino group, respectively (Figure 1D). Unfortunately, due to some limitations of the

enzymes and other issues, the methodology has not been widely adopted by other groups to prepare GSLs yet.

Despite the great advancements in GSL total synthesis²²⁻²⁵ and in carbohydrate chemistry at large, currently, access to homogenous GSLs and related derivatives remains difficult. In addition to problems associated with each individual synthetic strategy as mentioned above, a common and important issue about the reported strategies is that they are target-oriented, i.e., they are designed for synthesizing a specific GSL at a time. Therefore, although the strategies may give satisfactory results for certain GSLs, it is rather difficult to adopt them for the synthesis of a variety of GSLs and GSL derivatives at once. Hence, each synthetic target needs to be addressed as an independent challenge. Given the vast structural diversity of natural GSLs and their derivatives in demand, a general and facile method for the synthesis of these important molecules is highly desirable.

Results and Discussion

Our work aimed at establishing a robust, versatile, and scalable method to prepare GSLs and GSL derivatives. To this end, we have envisioned a novel diversity-oriented synthetic strategy, as outlined in Scheme 1, employing a simple glycoside **3** as the common starting material, which can be readily and efficiently prepared by glycosylation of a small head group of sphingosine **2** using a mono- or disaccharide core of GSL. Thereafter, the sugar and lipid moieties in **3** can be modified independently or in parallel to accomplish a diversity of GSLs and their functionalized derivatives rapidly. For example, glycosylation of **3** using either natural or unnatural sugar donors will provide **4A**, **4B**, and so on to have the glycan elongated. Then, the lipid moiety in each of these products will be remodelled to construct the ceramide moiety on-site *via* chemoselective reactions including cross-metathesis and *N*-acylation employing straight and/or functionalized olefins and *N*-acylating reagents, respectively, to provide different species of natural GSLs and their derivatives **4A-a** to **4A-x**, **4B-a** to **4B-x**, and so on. As the reactions involved in lipid remodelling are chemoselective and their conditions are very mild, labile molecular probes including fluorescent, radioactive, and chemical labels can be incorporated at this stage to obtain functionalized GSL derivatives that are useful for biological studies. On the other hand, the glycan in each of the products **4A**, **4B**, ... and **4Y** can be further elongated through glycosylation to yield more complex glycosides such as **5AA-5AY**, **5BA-5BY**, and so on. They can be subjected to lipid remodelling by the same method as mentioned to provide other GSLs and GSL derivatives.



Scheme 1. A diversity-oriented strategy for chemical synthesis of natural GSLs and GSL derivatives

To verify the above strategy, we applied it to the chemical synthesis of a unique lacto-ganglio series GSL, LcGg4 (**6**, Figure 2), having a GlcNAc and a GalNAc residues β -linked to the 3- and 4-*O*-positions of the Gal residue within the core lactose structure of GSLs, respectively.⁴⁶ LcGg4 was discovered in undifferentiated leukemia cells but its expression declined with differentiation and became virtually absent in differentiated M1⁺ cell.⁴⁷ Thus, it has been identified as a biomarker of undifferentiated, malignant myeloid cells useful for the development of novel diagnostics and therapeutics for cancer. LcGg4 is a minor GSL in nature, hence scientists had to rely on chemical synthesis to obtain sufficient quantities of homogeneous LcGg4 for biological studies.⁴⁸ However, LcGg4 represents a synthetic challenge, and to the best of our knowledge, currently, there has been only one reported total synthesis of LcGg4 by Ito et al.⁴⁸ On the other hand, there are many reports about the synthesis of other related, more complex lacto-ganglio GSLs, such as gangliosides X1 and X2.⁴⁹⁻⁵⁰ To further demonstrate the application scopes of the new synthetic strategy, we have

also applied it to the preparation of an artificial analog of LcGg4, namely **6a** (Figure 2), which had two GalNAc residues β -linked to the 3- and 4-*O*-positions of the Gal residue of the lactose moiety, as well as a series of its derivatives containing different lipids and unique molecular labels.






Figure 2: Structures of LcGg4 **6** and its analog **6a**

Our synthesis commenced with a large-scale preparation of the key building block lactoside **12** (Scheme 2), which has the functional head group of sphingosine β -linked to the downstream terminal (reducing end) anomeric position of lactose. Compound **12** can serve as the starting point for many GSLs, as most GSLs share this core structure. Multi-gram scale glycosylation of the head group of sphingosine **7**²⁷ with peracetylated lactosyl trichloroimidate **8**⁵¹ using $\text{BF}_3 \cdot \text{Et}_2\text{O}$ as the promoter was straightforward and stereoselective to afford **9** in an 81% yield. The newly generated β -glycosidic bond in **9** was confirmed by the large coupling constant ($J = 8.3$ Hz) of its anomeric ^1H signal (δ : 4.47 ppm) in the ^1H NMR spectrum. Selective deacetylation of the glycosylation product with NaOMe in methanol (pH 10) provided **10** in a 94% yield. Finally, **10** was converted into **11** in an excellent overall yield in three established steps including regioselective protection of the 3',4'-*O*-positions with isopropylidene, acetylation of the remaining hydroxyl groups, and then removal of the 3',4'-*O*-isopropylidene group with acetic acid. The structure of **12** was varied by NMR and MS data.



Scheme 2: Synthesis of the key building block **12**

Having the key building block **12** in hand, we proceeded to modify its glycan first (Scheme 3). We tried to prepare LcGg4 analog **6a** first, as it had two identical residues linked to lactose 3- and 4-*O*-positions and was thus believed to be easier to synthesize. Initially, we attempted to introduce both β -GalNAc residues to **12** at once, using *N,N*-diacetylgalactosamine thioglycoside⁵² **13** as the glycosyl donor and *N*-iodosuccinimide (NIS) and triflic acid (TfOH) as the promoters (Scheme 3A). We chose **13** because the first acetyl group of its *N,N*-diacetylamino group was supposed to be readily and selectively removed under mild conditions to afford the desired -NHAc group in one step, which might simplify global deprotection later. However, this reaction afforded only mono-glycosylated products **14** and **15** (2:1), even after prolonged reaction time using an excess of **13**, with partial *N*-deacetylation. The stereo- and regiochemistry of **14** and **15** were verified by their ¹H NMR data and by their ¹H-¹³C HMBC correlation NMR data, as correlations were observed between C-1 of GalNAc and H-3 of Gal (δ : 6.20 ppm) for **14** and between C-1 of GalNAc and H-4 of Gal (δ : 6.24 ppm) for **15**. More interestingly, in both **14** and **15** the GalNAc residue had an α -configuration ($J_{1'',2''}$ = 3.7 and 3.6 Hz, respectively), although the -NAc₂ group is deemed to be a participating group to usually favor 1,2-*trans* glycosylation. Clearly, **13** behaved strangely as a glycosyl donor, which is worth further investigation.




Scheme 3: Synthesis of branched tetrasaccharide **17**

To alleviate the above problem, we replaced **13** with *N*-(2,2,2-trichloroethoxy)carbonyl (Troc)-protected thioglycoside **16**⁵³ for the glycosylation of **12** (Scheme 3B). Under similar conditions, i.e., using NIS and TfOH as the promoters at -78 to -30 °C, **12** was smoothly glycosylated with **16** to provide **17** in excellent stereoselectivity and yield (82%). The structure of **17** was verified with NMR and MS data, and the β -stereochemistry of its newly formed glycosidic bonds was confirmed by the relatively large coupling constants ($J_{1'',2''} = 7.9$ and 8.8 Hz) between the H-1 (δ : 4.51 and 5.21 ppm) and H-2 signals of its two GalNTroc residues linked to the Gal 3-*O*- and 4-*O*-positions, respectively. The exclusive β -selectivity of this glycosylation reaction was most likely directed by the neighbouring group participation effect of the Troc group.

Subsequently, we assessed the reactions and conditions needed for remodelling the lipid in **17** and for on-site ceramide construction. In this regard, there are two potential strategies. One strategy is to attach the side chain *N*-acyl group first, followed by elongation of the sphingosine head group. The other strategy is to construct sphingosine first and introduce the *N*-acyl group thereafter. Each

of the two strategies can have its own advantages. For example, the former strategy can help reduce self-dimerization of the involved glycolipids during cross-metathesis because of increased steric hindrance around the olefin group; the latter strategy is more favourable for lipid functionalization involving various sensitive labels because *N*-acylation will be the last synthetic step before global deprotection and its reaction condition is mild. To examine the first strategy, as outlined in Scheme 4, the azido group in **17** was selectively reduced with triphenylphosphine to give the corresponding primary amine, which was then coupled with stearic acid under the influence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and 4-dimethylaminopyridine (DMAP) to afford **18** in an excellent overall yield (86%).⁵⁴ The construction of the sphingosine moiety was achieved by cross-metathesis.⁵⁵⁻⁵⁶ The reaction of **18** and 1-pentadecene **19** in the presence of the second-generation Hoveyda–Grubbs catalyst (**20**, 3 mol%) in refluxing dichloromethane was slow (5 days to finish) but clean to afford the desired *Z*-olefin **21** selectively in an excellent yield (88%), along with dimerization of **19**, whereas dimerization of **18** was not observed. The *Z*-configuration of the C=C double bond in **21** was confirmed by the coupling constant ($J = 15$ Hz) of its vinyl protons. The *N*-Troc groups in **21** were then replaced with acetyl groups upon their removal with Zn/AcOH and acetylation of the exposed free amino groups with Ac₂O in pyridine to provide **22**.⁵⁷ Finally, all of the *O*-acyl groups in **22** were removed with NaOMe in methanol (4.5 M) to produce the synthetic target, LcGg4 analog **6a**, in a good overall yield (54% for the last 3 steps).


To further test the above reaction conditions and demonstrate that the synthetic strategy can be employed to rapidly access different lipid forms of any GSL, we applied it subsequently to the preparation of different lipid form of **6a**, namely **6a*** (Scheme 4). Cross-metathesis of **18** and **19***, instead of **19**, gave **21***, which upon *N*-acyl group switching and global deprotection as described above afforded **6a*** containing a lipid moiety different from that of **6a**. Evidently, this procedure can be utilized to readily and rapidly access GSLs carrying other sphingosines; in the meantime, different fatty acids can be used to couple with the azide reduction product of **17** to prepare GSLs containing other *N*-acyl groups as well.



Scheme 4: Synthesis of LcGg4 analog **6a** and its different lipid form **6a***

After the reactions and conditions for lipid remodelling were optimized and verified with **6a** and **6a***, we moved on to the synthesis of LcGg4 **6** by a similar procedure. The glycosylation of diol **12** with *N*-Troc-protected glucosamine donor **23** (1.8 eq) under the promotion of NIS (1.8 eq) and TfOH (0.1 eq) was smooth and fast. To our surprise, however, this reaction afforded a mixture of mono- and di-glycosylated products **24** (12%) and **25** (72%) (SI: Table S1). The β -configuration of the GlcNTroc residue in **24** was confirmed by the relatively large coupling constant of its H-1 signal (δ 5.20 ppm, $J_{1,2} = 7.2$ Hz), and its regiochemistry was confirmed by the correlation between GlcNTroc C-1 and Gal H-3 (δ : 5.34 ppm) signals in its ^1H - ^{13}C HMBC NMR spectrum. For **25**, the β -configuration of its two GlcNTroc residues was also confirmed by the relatively large coupling constants ($J_{1,2} = 8.1$ and 8.4 Hz) of their H-1 signals. To improve the yield of monoglycosylation, different reaction conditions including various donor/acceptor ratios and concentrations were tried.

We found that reduced substrate concentration and donor equivalent were helpful. Finally, **24** was obtained in a 41% yield when only 1.1 eq of **23** was used, but under this condition di-glycosylated product **25** was still formed in substantial quantity (32%) (Scheme 5). The results indicated clearly that after 3'-O-glycosylation, the 4'-O-position in **24** was still very reactive.




Scheme 5: Total synthesis of LcGg4 **6**

Glycosylation of **24** with **16** under the above conditions went smoothly to provide **26** in a 75% yield. Its β -linked GalNTroc residue was verified with NMR data ($J_{1,2} = 8.7$ Hz). Subsequent lipid remodelling of **26** followed the same procedure as described for **6a** and **6a*** (Scheme 4), including reduction of the azide with triphenylphosphine to form the corresponding amine and acylation of the resultant amine with stearic acid, EDC and DMAP to afford **27** (82%), cross-metathesis of **27** and 1-pentadecene to give **28** (89%), substitution of the *N*-Troc groups in **28** with *N*-acetyl groups upon reduction with Zn/AcOH and *N*-acetylation with Ac_2O , and then global de-*O*-acylation with NaOMe, to finally produce **6** (Scheme 5). The *Z*-configuration of the C=C double bond in **28** was confirmed by the coupling constant ($J = 14.3$ Hz) of its vinyl protons.


We also assessed the other strategy for on-site ceramide construction starting from **17**, i.e., to assemble sphingosine first and introduce the *N*-acyl group next, as depicted in Scheme 6. Attempts for direct cross-metathesis of **17** and olefin were unsuccessful, probably due to the influence of the azido group. Then, the azido group in **17** was reduced, and the resultant amine was protected with

a *tert*-butyloxycarbonyl (Boc) group to obtain **30**. Cross-metathesis of **30** and **19** under the above conditions afforded **31** in an excellent yield (82%). At this stage, we chose to replace the *N*-Troc groups with *N*-acetyl groups by aforementioned method to convert **31** into **32** for subsequent lipid remodeling.⁵⁷ For subsequent *N*-acylation reaction, we chose fatty acid **33** that carried a fluorescent label, and our argument is that if it works, other simple fatty acids should work too. Accordingly, the *N*-Boc group in **32** was selectively removed with trifluoroacetic acid (TFA), and the resultant free amine was acylated with **33** using EDC and DMAP as the coupling reagents to provide **34** in an 83% yield. Finally, all of the *O*-acetyl groups in **34** were removed with NaOMe to provide LcGg4 analog **35** having a fluorescent label attached to the lipid moiety.



Scheme 6: Synthesis of fluorophore-tagged LcGg4 analog **35**

As discussed previously, another important and useful property of this new synthetic strategy is the convenience to achieve GSL diversity with the glycan. There are also two potential strategies for this. The first one is to introduce diversity in the glycan assembly stage by employing various natural and modified glycosyl donors for glycosylations, which has already been demonstrated by the synthesis of **6** and **6a** containing different glycans. Clearly, various series of natural GSLs and their derivatives can be easily achieved in this way. Another strategy is to introduce an orthogonal protecting group in the glycan during its assembly and then selectively remove this group at a later step for glycan modification. To demonstrate this, we selectively removed the *N*-Troc groups in **21** with Zn/AcOH, and acylated the resultant amine with 2-azidoacetic acid in the presence of EDC and DMAP to obtain **36** in a good yield (79%). Finally, global deprotection to remove all of the *O*-acyl groups in **36** with NaOMe produced another LcGg4 analog **37**, which contained two azido sugar residues (Scheme 7). The azido groups can be used as molecular handles to introduce labels *via* orthogonal click reaction to facilitate various biological studies and applications.



Scheme 7: Synthesis of azide-labeled LcGg4 analog **37**

Conclusion

In this study, we proposed a new strategy for diversity-oriented synthesis of GSLs and had verified the strategy with the synthesis of a lacto-ganglio GSL LcGg4 **6** and its analog **6a** that contained a different glycan, as well as a series of derivatives carrying a fluorophore or azido groups in the lipid or sugar moieties. An important feature of the new strategy is to start the synthesis of various

target molecules from the same simple building block **12** following the same protocols. Compound **12** consisting of the core of GSL glycans and the core of ceramides was readily and efficiently prepared from **7** and **8** on large scales. Another important feature of this strategy is that it allows stepwise elongation of the glycan in **12** using different glycosyl donors and remodeling of the lipid for on-site ceramide construction with different lipids after each glycosylation step, which could lead to a huge number of natural GSLs and functionalized GSL derivatives rapidly. The application scope of this synthetic strategy to various GSLs, as well as biological studies using the synthesized GSLs and their derivatives, is currently pursued in our laboratory.

Experimental Section

General Procedures. Chemicals and materials were purchased from commercial sources and were used as received without further purification unless otherwise noted. Molecular sieves 4Å (MS 4Å) were flame-dried under high vacuum and used immediately after being cooled to rt under a N₂ atmosphere. Analytical TLC was carried out on silica gel 60 Å F₂₅₄ plates with detection by a UV detector and/or by charring with 10% (v/v) H₂SO₄ in ethanol. Flash column chromatography was performed on silica gel 60 (230-400 Mesh). NMR spectra were acquired on a 600 MHz NMR spectrometer with chemical shifts reported in ppm (δ) referenced to CDCl₃ (¹H NMR: δ 7.26 ppm, ¹³C NMR: δ 77.16 ppm) or CD₃OD (¹H NMR: δ 3.31 ppm, ¹³C NMR: δ 49.0 ppm). Peak and coupling constant assignments are made based on ¹H NMR, ¹H-¹H COSY, ¹H-¹³C HSQC, and ¹H-¹³C HMBC experiments. Structural assignments were made with additional information from gCOSY, gHSQC, and gHMBC experiments. Aluminum heating blocks were used as the heating source for the reactions.

(2*S*,3*R*)-2-Azido-3-(pivaloyloxy)pent-4-en-1-yl 2,3,4,6-tetra-*O*-acetyl-β-*D*-galactopyranosyl-(1→4)-2,3,6-tri-*O*-acetyl-β-*D*-glucopyranoside (9): After a mixture of (3*R*,4*S*)-4-azido-5-hydroxypent-1-en-3-yl pivalate **7** (1.5 g, 6.6 mmol), 2,3,6,2',3',4',6'-septa-*O*-acetyl-β-lactosyl trichloroimidate **8** (7.2 g, 9.24 mmol), BF₃·Et₂O (0.174 mL, 1.32 mmol) and flame-dried MS 4Å (12 g) in dry CH₂Cl₂ (50 mL) was stirred at 0 °C for 60 min, it was allowed to warm to rt and stirred overnight. TLC showed complete consumption of the starting material, and then water was added in the reaction mixture. The organic layer was separated and washed with saturated aqueous NaHCO₃ solution, water, and brine and dried over Na₂SO₄. The solvent was evaporated in vacuo

and the residue was purified by column chromatography on silica gel to afford **9** (4.6 g, 81%) as a white solid. TLC: R_f = 0.6 (Hexane/EtOAc 7:3). ^1H NMR (600 MHz, CDCl_3): δ 5.78 (ddd, J = 17.5, 10.6, 6.7 Hz, 1H), 5.39 – 5.29 (m, 4H), 5.17 (t, J = 9.2 Hz, 1H), 5.09 (dd, J = 10.4, 7.9 Hz, 1H), 4.94 (dd, J = 10.4, 3.5 Hz, 1H), 4.89 (dd, J = 9.4, 7.8 Hz, 1H), 4.49 (d, J = 8.4 Hz, 1H anomeric), 4.48 (m, 1H), 4.47 (d, J = 8.3 Hz, 1H anomeric), 4.14 – 4.04 (m, 3H), 3.88 – 3.80 (m, 3H), 3.80 – 3.76 (m, 1H), 3.60 (ddd, J = 9.9, 5.0, 2.1 Hz, 1H), 3.51 (dd, J = 10.3, 5.8 Hz, 1H), 2.13 (s, 3H), 2.10 (s, 3H), 2.05 (s, 2 $\times$ 3H), 2.03 (s, 2 $\times$ 3H), 1.95 (s, 3H), 1.21 (s, 9H). $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3): δ 176.9, 170.5, 170.4, 170.2, 170.2, 169.9, 169.7, 169.2, 131.6, 120.4, 101.2, 100.4, 76.2, 73.7, 72.9, 72.8, 71.5, 71.1, 70.8, 69.2, 68.0, 66.7, 63.1, 61.9, 60.9, 39.0, 27.1, 20.9, 20.8, 20.7, 20.7, 20.7, 20.6. HRMS (ESI-TOF) m/z : $[\text{M} + \text{Na}]^+$ Calcd for $\text{C}_{36}\text{H}_{51}\text{N}_3\text{O}_{20}\text{Na}$ 868.2958; Found 868.2984.

(2S,3R)-2-Azido-3-(pivaloyloxy)pent-4-en-1-yl β -D-galactopyranosyl-(1 $\rightarrow$ 4)- β -D-glucopyranoside (10): To a solution of **9** (4.6 g, 5.44 mmol) dissolved in THF/MeOH (1:1, v/v, 50 mL) was added a solution of MeONa in MeOH (0.4 M) at 0 $^\circ\text{C}$ until the pH reached 10. The solution was stirred at rt (~ 23 $^\circ\text{C}$) for 6 h. When TLC showed the completion of reaction indicated by one single spot, the reaction was neutralized to pH 6-7 with Amberlyst (H^+) resin. The resin was removed by filtration and the filtrate was concentrated under *vacuo* to give the crude product, which was purified by flash column chromatography (MeOH/ CH_2Cl_2) to give **10** (2.8 g, 94%) as a white solid. TLC: R_f = 0.4 (CH_2Cl_2 /MeOH 4:1). ^1H NMR (600 MHz, CD_3OD): δ 5.95 – 5.80 (m, 1H), 5.48 (m, 1H), 5.38 (dt, J = 17.2, 1.3 Hz, 1H), 5.34 (dt, J = 10.6, 1.3 Hz, 1H), 4.36 (d, J = 7.7 Hz, 1H anomeric), 4.32 (d, J = 7.8 Hz, 1H anomeric), 4.01 (ddd, J = 7.5, 5.5, 3.9 Hz, 1H), 3.93 – 3.88 (m, 2H), 3.87 – 3.83 (m, 1H), 3.81 (dd, J = 3.3, 1.0 Hz, 1H), 3.78 (dd, J = 11.4, 7.5 Hz, 1H), 3.70 (dd, J = 11.4, 4.6 Hz, 1H), 3.64 (dd, J = 10.6, 5.5 Hz, 1H), 3.61 – 3.55 (m, 2H), 3.55 – 3.50 (m, 2H), 3.48 (dd, J = 9.7, 3.3 Hz, 1H), 3.43 – 3.41 (m, 1H), 3.27 (dd, J = 9.1, 7.8 Hz, 1H), 1.24 (s, 9H). $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CD_3OD): δ 178.5, 133.0, 120.2, 105.0, 104.4, 80.5, 75.5, 74.8, 74.6, 72.5, 70.3, 69.3, 64.9, 62.4, 61.9, 49.4, 49.2, 49.1, 49.0, 48.8, 48.7, 48.5, 39.9 27.4. HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ Calcd. for $\text{C}_{22}\text{H}_{38}\text{N}_3\text{O}_{13}$ 552.2399; Found 552.2374.

(2S,3R)-2-Azido-3-(pivaloyloxy)pent-4-en-1-yl 3,4-O-isopropylidene- β -D-galactopyranosyl-(1 $\rightarrow$ 4)- β -D-glucopyranoside (11): After a suspension of **10** (2.8 g, 5.08 mmol) and anhydrous *p*-

toluene sulphonic acid (0.241 g, 1.27 mmol) in 2,2-dimethoxypropane (30 mL) was stirred at rt for 20 h, it was diluted with methanol. Water (5 mL) was added, and the solution was neutralised with triethylamine (5 mL) and then concentrated in vacuum. The residue was purified by column chromatography to give **11** as a white solid (2.6 g, 86%). TLC: R_f = 0.7 (CH₂Cl₂/MeOH 4:1). ¹H NMR (600 MHz, CD₃OD): δ 5.90 (ddd, J = 17.2, 10.6, 6.6 Hz, 1H), 5.50 (dd, J = 6.2, 4.4 Hz, 1H), 5.42 – 5.37 (m, 1H), 5.36–5.34 (m, 1H), 4.38 (d, J = 7.7 Hz, 1H anomeric), 4.34 (d, J = 7.8 Hz, 1H anomeric), 4.21 (dd, J = 5.6, 2.0 Hz, 1H), 4.07 (dd, J = 7.4, 5.5 Hz, 1H), 4.05 – 4.00 (m, 1H), 3.97–3.94 (m, 1H), 3.93 – 3.87 (m, 2H), 3.87 – 3.73 (m, 3H), 3.66 (dd, J = 10.7, 5.4 Hz, 1H), 3.60–3.52 (m, 2H), 3.50 – 3.41 (m, 2H), 3.29 (dd, J = 9.2, 7.7 Hz, 1H), 1.49 (s, 3H), 1.34 (s, 3H), 1.25 (s, 9H). ¹³C{¹H} NMR (150 MHz, CD₃OD): δ 178.5, 133.0, 120.2, 111.1, 104.3, 104.1, 80.8, 80.8, 76.4, 76.2, 75.5, 75.3, 75.0, 74.7, 74.4, 69.3, 64.9, 62.4, 61.8, 39.9, 28.4, 27.5, 26.5. HRMS (ESI-TOF) m/z : [M + Na]⁺ Calcd for C₂₅H₄₁N₃O₁₃Na 614.2531; Found 614.2532.

(2S,3R)-2-Azido-3-(pivaloyloxy)pent-4-en-1-yl 2,6-di-O-acetyl- β -D-galactopyranosyl-(1 $\rightarrow$ 4)-2,3,6-tri-O-acetyl- β -D-glucopyranoside (12): To a solution of **11** (2.6 g, 4.39 mmol) in pyridine (30 mL) was added acetic anhydride (5.6 mL, 65.9 mmol) dropwise over 10 min at 0 °C, and the solution was stirred overnight and then diluted with EtOAc (50 mL). The mixture was washed with 45 mL of 2 N HCl and 50 mL of sat. NaHCO₃ solution and brine, and then dried (Na₂SO₄), filtered, and concentrated in *vacuo* to yield (2S,3R)-2-azido-3-(pivaloyloxy)pent-4-en-1-yl 2,6-di-O-acetyl-3,4-O-isopropylidene- β -D-galactopyranosyl-(1 $\rightarrow$ 4)-2,3,6-tri-O-acetyl- β -D-glucopyranoside (**11a**, 3.25 g, 92%) as a pale-yellow foamy solid. TLC: R_f = 0.8 (EtOAc). ¹H NMR (600 MHz, CDCl₃): δ 5.78 (ddd, J = 17.3, 10.5, 6.8 Hz, 1H), 5.44 – 5.24 (m, 3H), 5.15 (t, J = 9.3 Hz, 1H), 4.90 (dd, J = 9.5, 7.8 Hz, 1H), 4.86 – 4.81 (m, 1H), 4.47 (d, J = 7.9 Hz, 1H anomeric), 4.43 (dd, J = 12.0, 2.1 Hz, 1H), 4.36 (d, J = 7.4 Hz, 1H anomeric), 4.32 – 4.20 (m, 2H), 4.15 – 4.08 (m, 3H), 3.91 (ddd, J = 6.9, 4.8, 1.6 Hz, 1H), 3.83 (dd, J = 10.3, 6.6 Hz, 1H), 3.80 – 3.72 (m, 2H), 3.60 (ddd, J = 9.8, 5.2, 2.1 Hz, 1H), 3.51 (dd, J = 10.4, 5.8 Hz, 1H), 2.11 (s, 3H), 2.09 (s, 3H), 2.06 (s, 3H), 2.04 (s, 3H), 2.03 (s, 3H), 1.51 (s, 3H), 1.29 (s, 3H), 1.20 (s, 9H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 176.9, 170.8, 170.4, 170.0, 169.6, 169.2, 131.5, 120.3, 110.96, 100.6, 100.4, 76.9, 76.0, 73.7, 73.1, 73.0, 72.8, 72.5, 71.5, 71.0, 67.9, 63.2, 63.1, 62.1, 39.0, 27.4, 27.1, 26.2, 20.9, 20.9, 20.9, 20.8, 20.7. HRMS (ESI-TOF) m/z : [M + Na]⁺ Calcd for C₃₅H₅₁N₃O₁₈Na 824.3060; Found 824.3059. After **11a** (3.2 g, 3.99 mmol) was dissolved in 80%

aqueous AcOH (25 mL), the solution was kept at 80 °C for 1 h when TLC indicated the complete disappearance of starting material. Acetic acid was removed in vacuum and the residue was co-evaporated with toluene (3 × 20 mL) and then purified by column chromatography on a silica gel column to provide **12** (2.6 g, 84%). TLC: R_f = 0.45 (EtOAc/MeOH, 40:1). ^1H NMR (600 MHz, CDCl_3): δ 5.79 (ddd, J = 17.3, 10.5, 6.8 Hz, 1H), 5.41 – 5.30 (m, 3H), 5.16 (t, J = 9.3 Hz, 1H), 4.93 (dd, J = 9.6, 7.9 Hz, 1H), 4.88 (dd, J = 9.8, 7.8 Hz, 1H), 4.51 – 4.48 (m, 2H), 4.38 – 4.30 (m, 2H), 4.22 (dd, J = 11.4, 6.5 Hz, 1H), 4.14 (dd, J = 12.0, 5.3 Hz, 1H), 3.94 – 3.81 (m, 2H), 3.81 – 3.71 (m, 2H), 3.66 – 3.56 (m, 3H), 3.53 (dd, J = 10.4, 5.8 Hz, 1H), 3.36 (d, J = 7.4 Hz, 1H), 3.14 (d, J = 5.5 Hz, 1H), 2.15 – 2.08 (3s, 9H), 2.06 (s, 3H), 2.04 (s, 3H), 1.22 (s, 9H). $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3): δ 176.9, 171.5, 171.1, 170.5, 170.5, 169.6, 131.6, 120.4, 101.0, 100.5, 76.2, 73.7, 73.6, 73.0, 72.8, 72.7, 72.3, 71.3, 68.5, 68.0, 63.2, 62.4, 62.2, 39.0, 27.1, 21.0, 20.9, 20.9, 20.9, 20.8. HRMS (ESI-TOF) m/z : $[\text{M} + \text{Na}]^+$ Calcd for $\text{C}_{32}\text{H}_{47}\text{N}_3\text{O}_{18}\text{Na}$ 784.2746; Found 784.2750.

(2S,3R)-2-Azido-3-(pivaloyloxy)pent-4-en-1-yl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy- α -D-galactopyranosyl-(1→3)-2,6-di-O-acetyl- β -O-D-galactopyranosyl-(1→4)-2,3,6-tri-O-acetyl- β -D-glucopyranoside (14) and (2S,3R)-2-Azido-3-(pivaloyloxy)pent-4-en-1-yl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy- α -D-galactopyranosyl-(1→4)-2,6-di-O-acetyl- β -D-galactopyranosyl-(1→4)-2,3,6-tri-O-acetyl- β -D-glucopyranoside (15): After a mixture of **12** (40 mg, 0.52 mmol), **13** (78 mg, 0.157 mmol), and flame-dried MS 4Å in dry CH_2Cl_2 (4 mL) was stirred at rt for 30 min, it was cooled to -78 °C and NIS (41 mg, 0.184 mmol) was added, which followed by TfOH (0.5 μL , 0.005 mmol). The mixture was warmed to -40 to -30 °C and stirred at this temperature for 2 h, and the reaction was quenched with triethyl amine (1 mL). The mixture was diluted with CH_2Cl_2 and filtered through a Celite pad. The CH_2Cl_2 layer was washed with saturated $\text{Na}_2\text{S}_2\text{O}_3$ solution, saturated aqueous NaHCO_3 solution, water, and brine and then dried with Na_2SO_4 . The solvent was evaporated in vacuo and the residue was purified by silica gel column chromatography to afford **14** (28 mg, 48%) and **15** (14 mg, 24%) as off-white solids. Compound **14**: TLC: R_f = 0.3 (EtOAc/Toluene 3:2). ^1H NMR (600 MHz, CDCl_3): δ 6.20 (d, J = 3.6 Hz, 1H), 5.79 (ddd, J = 17.3, 10.5, 6.8 Hz, 1H), 5.47 (d, J = 9.2 Hz, 1H), 5.41 (d, J = 2.3 Hz, 1H), 5.38 – 5.31 (m, 3H), 5.21 (dd, J = 11.5, 3.2 Hz, 1H), 5.15 (t, J = 9.3 Hz, 1H), 4.92 (dd, J = 9.5, 8.0 Hz, 1H), 4.87 (dd, J = 9.6, 8.0 Hz, 1H), 4.72 (ddd, J = 11.7, 9.3, 3.7 Hz, 1H), 4.54 – 4.44 (m, 2H), 4.35 – 4.32 (m, 2H), 4.27 –

4.19 (m, 2H), 4.17 – 4.11 (m, 1H), 4.11 – 4.03 (m, 2H), 3.88 – 3.80 (m, 2H), 3.81 – 3.73 (m, 2H), 3.65 – 3.61 (m, 3H), 3.59 (dd, $J = 9.7, 3.5$ Hz, 1H), 3.52 (dd, $J = 10.4, 5.8$ Hz, 1H), 2.16 (s, 3H), 2.11 (brs, 3×3 H), 2.05 (s, 3H), 2.03 (s, 3H), 2.02 (brs, 2×3 H), 1.94 (s, 3H), 1.21 (s, 9H). $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3): δ 176.9, 171.5, 171.3, 171.1, 170.5, 170.4, 170.3, 170.2, 169.6, 168.9, 131.6, 120.3, 100.9, 100.4, 91.4, 76.2, 73.7, 73.7, 73.0, 72.8, 72.7, 72.3, 71.3, 68.6, 68.4, 68.0, 68.0, 66.8, 63.2, 62.4, 62.2, 61.4, 47.1, 39.0, 27.1, 23.3, 21.0, 21.0, 20.9, 20.9, 20.8, 20.8, 20.8, 20.7. HRMS (ESI-TOF) m/z : $[\text{M} + \text{Na}]^+$ Calcd. for $\text{C}_{46}\text{H}_{66}\text{N}_4\text{O}_{26}\text{Na}$ 1113.3857; Found. 1113.3874.

Compound **15**: TLC: $R_f = 0.5$ (EtOAc/Toluene, 3:2). ^1H NMR (600 MHz, CDCl_3): δ 6.24 (d, $J = 3.6$ Hz, 1H, anomeric), 5.79 (ddd, $J = 17.3, 10.5, 6.8$ Hz, 1H), 5.59 (d, $J = 9.1$ Hz, 1H), 5.45 (d, $J = 2.2$ Hz, 1H), 5.39 – 5.30 (m, 3H), 5.24 (dd, $J = 11.6, 3.2$ Hz, 1H), 5.15 (t, $J = 9.3$ Hz, 1H), 4.92 (dd, $J = 9.5, 7.9$ Hz, 1H), 4.86 (dd, $J = 9.6, 8.0$ Hz, 1H), 4.77 (ddd, $J = 11.7, 9.2, 3.6$ Hz, 1H), 4.58 – 4.45 (m, 2H), 4.35 – 4.32 (m, 3H), 4.22 (dd, $J = 11.4, 6.5$ Hz, 1H), 4.18 – 4.09 (m, 2H), 4.06 (dd, $J = 11.4, 6.7$ Hz, 1H), 3.90 – 3.71 (m, 5H), 3.62 (q, $J = 6.1, 5.6$ Hz, 2H), 3.59 (dd, $J = 9.7, 3.3$ Hz, 1H), 3.53 (dd, $J = 10.4, 5.8$ Hz, 1H), 2.17 (s, 3H), 2.10 (brs, 3×3 H), 2.05 (s, 3H), 2.03 (brs, 3×3 H), 1.96 (s, 3H), 1.21 (s, 9H). $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) δ 176.9, 171.5, 171.3, 171.1, 170.5, 170.5, 170.4, 170.3, 170.3, 169.6, 167.1, 131.6, 120.3, 100.9, 100.4, 92.6, 76.2, 73.7, 73.7, 73.0, 72.8, 72.7, 72.3, 71.3, 69.2, 68.4, 68.0, 67.8, 66.8, 63.2, 62.4, 62.2, 61.4, 47.4, 39.0, 27.1, 23.2, 21.0, 20.9 (2C), 20.9, 20.8, 20.8, 20.8 (3C). HRMS (ESI-TOF) m/z : $[\text{M} + \text{Na}]^+$ Calcd. for $\text{C}_{46}\text{H}_{66}\text{N}_4\text{O}_{26}\text{Na}$ 1113.3863; Found. 1113.3854.

(2S,3R)-2-Azido-3-(pivaloyloxy)pent-4-en-1-yl 3,4,6-tri-O-acetyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)- β -D-galactopyranosyl-(1 $\rightarrow$ 3)-[3,4,6-tri-O-acetyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)- β -D-galactopyranosyl-(1 $\rightarrow$ 4)]-2,6-di-O-acetyl- β -D-galactopyranosyl-(1 $\rightarrow$ 4)-2,3,6-tri-O-acetyl- β -D-glucopyranoside (17): After a mixture of **12** (1.2 g, 1.58 mmol), **16** (3.7 g, 6.30 mmol), and flame-dried MS 4Å in dry CH_2Cl_2 (12 mL) was stirred at rt for 30 min, it was cooled to -78°C and NIS (1.95 g, 8.66 mmol) was added, which was followed by TfOH (28 μL , 0.315 mmol). The mixture was stirred at -40 to -30°C for 2 h, and the reaction was quenched with triethyl amine (1 mL). The mixture was diluted with CH_2Cl_2 and filtered through a Celite pad. The CH_2Cl_2 layer was washed with saturated $\text{Na}_2\text{S}_2\text{O}_3$ solution, saturated NaHCO_3 solution, water, and brine and then dried with Na_2SO_4 . The solvent was evaporated in vacuo and the residue was purified by silica gel column chromatography to afford

17 (2 g, 82%) as an off-white solid. TLC: R_f = 0.52 (Toluene/EtOAc 3:2). ^1H NMR (600 MHz, CDCl_3): δ 6.12 (d, J = 10.0 Hz, 1H, -NH), 5.78 (ddd, J = 17.4, 10.5, 6.8 Hz, 1H, =CH-), 5.40 (d, J = 3.0 Hz, 1H), 5.38 – 5.30 (m, 4H), 5.26 (d, J = 12.6 Hz, 1H, $-\text{OCH}_2\text{CCl}_3$), 5.22 (d, J = 8.6 Hz, 1H, anomeric), 5.19 – 5.07 (m, 3H), 5.05 – 5.00 (m, 1H), 4.96 – 4.92 (m, 3H), 4.62 (d, J = 12.1 Hz, 1H, $-\text{OCH}_2\text{CCl}_3$), 4.55 (d, J = 12.6 Hz, 1H, $-\text{OCH}_2\text{CCl}_3$), 4.52 (d, J = 8.2 Hz, 1H, anomeric), 4.46 (d, J = 7.8 Hz, 1H, anomeric), 4.42 (d, J = 11.3 Hz, 1H, $-\text{OCH}_2\text{CCl}_3$), 4.32 – 4.17 (m, 4H), 4.15 – 4.02 (m, 6H), 3.92 – 3.88 (m, 2H), 3.85 – 3.75 (m, 3H), 3.73 – 3.69 (m, 1H), 3.68 – 3.65 (m, 1H), 3.63 – 3.58 (m, 1H), 3.58 – 3.56 (m, 1H), 3.51 (dd, J = 10.2, 5.7 Hz, 1H, $-\text{OCH}_2\text{-CHN}_3$), 2.19 (s, 3H), 2.17 (s, 3H), 2.10 (s, 3H), 2.10 (s, 3H), 2.07 (s, 3H), 2.05 (s, 6H, 2 x CH_3), 2.02 (s, 3H), 2.01 (s, 3H), 2.00 (s, 3H), 1.97 (s, 3H), 1.21 (s, 9H, -OPiv). $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3): δ 176.8, 170.9, 170.8, 170.6, 170.5, 170.4, 170.3, 170.2, 170.1, 169.8, 169.5, 168.31, 155.3, 154.4, 131.4, 120.2, 102.9, 100.7, 100.6, 100.3, 96.5, 95.3, 79.7, 74.9, 74.2, 73.6, 73.0, 72.5, 71.9, 71.5, 71.2, 70.9, 70.8, 70.0, 68.3, 67.9, 66.5, 66.4, 63.2, 63.1, 62.0, 61.4, 61.0, 52.9, 52.0, 38.9, 27.0, 20.8, 20.8, 20.7, 20.7, 20.6, 20.6, 20.6, 20.5, 20.5, 20.4. HRMS (ESI-TOF) m/z : $[\text{M} + \text{Na}]^+$ Calcd. for $\text{C}_{62}\text{H}_{83}\text{Cl}_6\text{N}_5\text{O}_{36}\text{Na}$ 1708.2825; Found 1708.2851.

(2S,3R)-2-Octadecanamido-3-(pivaloyloxy)pent-4-en-1-yl 3,4,6-tri-O-acetyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)- β -D-galactopyranosyl-(1 $\rightarrow$ 3)-[3,4,6-tri-O-acetyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)- β -D-galactopyranosyl-(1 $\rightarrow$ 4)]-2,6-di-O-acetyl- β -D-galactopyranosyl-(1 $\rightarrow$ 4)-2,3,6-tri-O-acetyl- β -D-glucopyranoside (18): After PPh_3 (161.6 mg, 0.616 mmol) and water (55.5 μL , 3.08 mmol) were added to a stirred solution of **17** (520 mg, 0.308 mmol) in THF (6 mL), the mixture was heated with stirring at 50 $^\circ\text{C}$ using an aluminium heating block until TLC indicated the disappearance of **17**. The solvents were removed under vacuum, and the residue was dissolved in dry CH_2Cl_2 (6 mL). Then, EDC (118 mg, 0.616 mmol), DMAP (0.7 mg, 0.006 mmol) and stearic acid (175.4 mg, 0.616 mmol) were added under argon, and the mixture was stirred at rt for 12 h. The solvent was removed in *vacuo* and the residue was purified by silica gel column chromatography to afford **18** (515 mg, 86%) as a white powder. TLC: R_f = 0.8 (EtOAc). ^1H NMR (600 MHz, CDCl_3): δ 6.11 (d, J = 10.1 Hz, 1H, -NH), 5.78 (ddd, J = 17.0, 10.6, 6.1 Hz, 1H), 5.67 (d, J = 9.2 Hz, 1H, -NH), 5.41 (d, J = 3.3 Hz, 1H), 5.35 (d, J = 3.4 Hz, 1H), 5.33 – 5.27 (m, 3H), 5.25 (dt, J = 10.5, 1.2 Hz, 1H), 5.22 (d, J = 8.8 Hz, 1H, anomeric), 5.18 – 5.08 (m, 3H), 5.02 (dd, J = 11.3, 3.4 Hz, 1H), 4.96 (d, J = 12.3 Hz, 1H, $-\text{OCH}_2\text{CCl}_3$), 4.94 – 4.92

(m, 1H), 4.88 (dd, $J = 9.9, 7.8$ Hz, 1H, $-\text{OCH}_2\text{CCl}_3$), 4.62 (d, $J = 12.1$ Hz, 1H, $-\text{OCH}_2\text{CCl}_3$), 4.54 (d, $J = 12.7$ Hz, 1H, $-\text{OCH}_2\text{CCl}_3$), 4.50 (d, $J = 8.2$ Hz, 1H, anomeric), 4.42 – 4.35 (m, 3H, 1 anomeric H), 4.30 – 4.18 (m, 5H, 1 anomeric H), 4.17 – 4.13 (m, 2H), 4.09 – 4.02 (m, 4H), 3.94 (dd, $J = 9.9, 3.6$ Hz, 1H), 3.97 – 3.88 (m, 2H), 3.86 – 3.79 (m, 1H), 3.67 (dd, $J = 11.3, 8.1$ Hz, 2H), 3.62 (t, $J = 5.9$ Hz, 1H), 3.60 – 3.54 (m, 1H), 3.51 (dd, $J = 9.9, 4.6$ Hz, 1H), 2.20 (s, 3H), 2.18 (s, 3H), 2.12 (s, 3H (CH_3), 2H, $(-\text{CH}_2\text{CH}_2\text{CO})$), 2.11 (s, 3H), 2.09 (s, 3H), 2.06 (s, 3H), 2.04 (s, 2 $\times$ 3H), 2.02 (s, 3H), 2.01 (s, 3H), 1.98 (s, 3H), 1.62 – 1.52 (m, 2H), 1.30 – 1.24 (m, 30H), 1.19 (s, 9H), 0.87 (t, $J = 7.0$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3): δ 177.0, 172.8, 170.9, 170.9, 170.6, 170.6, 170.4, 170.2, 169.8, 168.4, 155.4, 154.5, 133.3, 118.9, 103.2, 100.9, 100.4, 96.6, 95.4, 79.8, 75.1, 74.9, 74.4, 74.3, 73.1, 73.1, 72.6, 72.1, 71.5, 71.4, 71.1, 70.9, 70.0, 68.4, 67.7, 66.6, 66.5, 63.3, 62.2, 61.5, 61.0, 53.1, 52.2, 50.2, 38.9, 36.9, 32.0, 29.8, 29.7, 29.7, 29.6, 29.5, 29.4, 29.4, 29.4, 27.5, 27.1, 25.8, 22.8, 20.9, 20.9, 20.8, 20.8, 20.7, 20.7, 20.7, 20.6, 14.2, 9.4. HRMS (ESI-TOF) m/z : $[\text{M} + \text{Na}]^+$ Calcd. for $\text{C}_{80}\text{H}_{119}\text{Cl}_6\text{N}_3\text{O}_{37}\text{Na}$ 1950.5525; Found 1950.5602.

(2*S*,3*R*,*E*)-2-Octadecanamido-3-(pivaloyloxy)octadec-4-en-1-yl 3,4,6-tri-*O*-acetyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)- β -D-galactopyranosyl-(1 $\rightarrow$ 3)-[3,4,6-tri-*O*-acetyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)- β -D-galactopyranosyl-(1 $\rightarrow$ 4)]-2,6-di-*O*-acetyl- β -D-galactopyranosyl-(1 $\rightarrow$ 4)-2,3,6-tri-*O*-acetyl- β -D-glucopyranoside (21**):** To a solution of **18** (510 mg, 0.264 mmol) and pentadecene-1 **19** (0.359 mL, 1.32 mmol) in dry CH_2Cl_2 (25 mL) was added Hoveyda–Grubbs second-generation catalyst (**20**, 50 mg, 0.079 mmol). The mixture was heated to reflux using an aluminium heating block for 5 days. After every 24 h, another batch of **19** (0.35 mL, 1.32 mmol) and Hoveyda–Grubbs second-generation catalyst (10 mol%) was added. After reaction was completed, 2 drops of DMSO was added in the mixture at rt followed by stirring for an additional 2 h. The mixture was concentrated, and product was purified by silica gel column chromatography to give **21** (492 mg, 88%) as a white glassy solid. TLC: $R_f = 0.4$ (Hex/EtOAc 2:3). ^1H NMR (600 MHz, CDCl_3): δ 6.10 (d, $J = 10.1$ Hz, 1H, $-\text{NH}$), 5.75 (ddd, $J = 14.4, 6.8$ Hz, 1H, $=\text{CH}-$), 5.61 (d, $J = 9.3$ Hz, 1H, $-\text{NH}$), 5.41 (d, $J = 3.3$ Hz, 1H), 5.38 – 5.30 (m, 3H), 5.25 – 5.19 (m, 2H), 5.15 – 5.07 (m, 3H), 5.03 (dd, $J = 11.3, 3.4$ Hz, 1H), 5.00 – 4.92 (m, 2H), 4.89 (dd, $J = 9.9, 7.8$ Hz, 1H), 4.63 (d, $J = 12.1$ Hz, 1H, $-\text{OCH}_2\text{CCl}_3$), 4.55 (d, $J = 12.6$ Hz, 1H, $-\text{OCH}_2\text{CCl}_3$), 4.50 (d, $J = 8.2$ Hz, 1H, anomeric), 4.42 – 4.38 (m, 2H, 1 anomeric H), 4.35 – 4.31 (m, 1H), 4.30 – 4.18 (m, 5H), 4.17 – 4.12 (m, 2H), 4.11 – 3.99 (m, 3H), 3.95 – 3.88 (m, 3H), 3.85 – 3.80 (m,

1H), 3.70 – 3.64 (m, 2H), 3.63 – 3.60 (m, 1H), 3.56 (dt, $J = 9.2, 3.9$ Hz, 1H), 3.48 (dd, $J = 9.8, 4.4$ Hz, 1H), 2.20 (s, 3H), 2.19 (s, 3H), 2.13 (s, 3H (CH_3)), 2H, ($-CH_2CH_2CO$), 2.11 (s, 3H), 2.10 (s, 3H), 2.08 (s, 3H), 2.04 (s, 3H), 2.03 (s, 3H), 2.02 (s, 3H), 2.02 (s, 3H), 1.98 (s, 3H), 1.58 – 1.55 (m, 3H), 1.34 – 1.21 (m, 52H), 1.16 (s, 9H), 0.88 (t, $J = 7.0$ Hz, 6H). $^{13}C\{^1H\}$ NMR (150 MHz, $CDCl_3$): δ 177.0, 172.6, 170.9, 170.6, 170.6, 170.4, 170.4, 170.2, 169.9, 169.8, 168.4, 155.4, 154.5, 137.2, 124.9, 103.2, 100.9, 100.8, 100.4, 96.6, 95.4, 79.9, 75.1, 74.9, 74.4, 73.0, 72.6, 72.1, 71.5, 71.4, 71.1, 70.9, 70.0, 68.4, 67.7, 66.6, 66.5, 63.3, 62.2, 61.5, 61.0, 53.1, 52.1, 50.4, 38.9, 37.0, 32.4, 32.0, 29.8, 29.8, 29.6, 29.6, 29.5, 29.5, 29.3, 29.1, 27.5, 27.1, 25.8, 22.8, 21.0, 20.9, 20.9, 20.8, 20.8, 20.7, 20.7, 20.6, 14.2. HRMS (ESI-TOF) m/z : $[M + NH_4]^+$ Calcd. for $C_{93}H_{149}Cl_6N_4O_{37}$ 2124.8013; Found 2124.8021.

(2*S*,3*R*,*E*)-2-Octadecanamido-3-(pivaloyloxy)octadec-4-en-1-yl 2-actamino-3,4,6-tri-*O*-acetyl-2-deoxy- β -D-galactopyranosyl-(1 $\rightarrow$ 3)-[2-actamino-3,4,6-tri-*O*-acetyl-2-deoxy- β -D-

galactopyranosyl-(1 $\rightarrow$ 4)]-2,6-di-*O*-acetyl- β -D-galactopyranosyl-(1 $\rightarrow$ 4)-2,3,6-tri-*O*-acetyl- β -D-

glucopyranoside (22): To a solution of **21** (21 mg, 0.009 mmol) in AcOH/THF (2:3, 2 mL) was added activated Zn (33 mg). After the mixture was stirred at rt for 12 h, it was filtered through a *Celite* pad and the solution was concentrated under reduced pressure. The crude product was dissolved in pyridine (1 mL) and Ac_2O (0.7 mL) at 0 °C, and the solution was stirred at rt overnight. After completion of the reaction, the solution was concentrated under vacuum and the product was purified by silica gel column chromatography to afford **22** (14 mg, 76%); TLC: $R_f = 0.25$ (EtOAc). 1H NMR (600 MHz, $CDCl_3$): δ 6.72 (d, $J = 8.6$ Hz, 1H, -NH), 6.02 (d, $J = 7.9$ Hz, 1H, -NH), 5.75 (dt, $J = 14.3, 6.7$ Hz, 1H, =CH-), 5.61 (d, $J = 9.3$ Hz, 1H, -NH), 5.54 (bd, $J = 11.3$ Hz, 1H), 5.44 – 5.30 (m, 5H), 5.22 (t, $J = 7.4$ Hz, 1H), 5.15 (t, $J = 9.4$ Hz, 1H), 4.95 (dd, $J = 10.0, 7.9$ Hz, 1H), 4.89 (dd, $J = 9.7, 7.8$ Hz, 1H), 4.76 (d, $J = 8.2$ Hz, 1H, anomeric), 4.40 (t, $J = 9.4$ Hz, 2H), 4.36 – 4.30 (m, 1H), 4.29 – 4.22 (m, 2H), 4.21 – 4.10 (m, 5H), 4.08 – 4.03 (m, 3H), 3.95 – 3.86 (m, 3H), 3.77 (t, $J = 8.9$ Hz, 1H), 3.72 (t, $J = 9.6$ Hz, 1H), 3.66 (dd, $J = 9.9, 3.3$ Hz, 1H), 3.61 (t, $J = 6.0$ Hz, 1H), 3.60 – 3.55 (m, 1H), 3.49 (dd, $J = 9.9, 4.4$ Hz, 1H), 2.19 (2s, 6H), 2.12 (brs, 5H, -CH₃, -CHCH₂CO-), 2.11 (s, 3H), 2.09 (s, 3H), 2.08 (s, 3H), 2.06 (s, 3H), 2.04 (2s, 6H), 2.03 (s, 3H), 2.02 (s, 3H), 2.00 (s, 3H), 1.92 (s, 3H), 1.59 – 1.52 (m, 2H), 1.34 – 1.20 (m, 52H), 1.17 (s, 9H), 0.88 (t, $J = 6.9$ Hz, 6H). $^{13}C\{^1H\}$ NMR (150 MHz, $CDCl_3$): δ 177.0, 172.6, 171.9, 171.0, 170.8, 170.7, 170.6, 170.6, 170.6, 170.4, 170.4, 170.3, 170.0, 169.8, 168.9, 137.2, 124.9, 101.5, 100.8, 100.2,

99.8, 78.4, 74.9, 73.1, 73.0, 72.4, 72.2, 72.1, 71.7, 71.2, 71.0, 70.7, 70.0, 68.3, 67.7, 66.9, 66.8, 63.3, 62.3, 61.6, 61.1, 52.4, 50.5, 38.9, 37.0, 32.4, 32.0, 31.0, 29.8, 29.8, 29.8, 29.6, 29.6, 29.5, 29.5, 29.3, 29.1, 27.1, 25.8, 23.5, 23.4, 22.8, 21.0, 21.0, 20.9, 20.9, 20.9, 20.8, 20.8, 20.7, 20.7, 14.2. HRMS (ESI-TOF) m/z : $[M + Na]^+$ Calcd. for $C_{91}H_{147}N_3O_{35}Na$ 1865.9707; Found 1865.9742.

(2*S*,3*R*,*E*)-2-Octadecanamido-3-hydroxyoctadec-4-en-1-yl 2-actamino-2-deoxy- β -D-galactopyranosyl-(1 $\rightarrow$ 3)-[2-actamino-2-deoxy- β -D-galactopyranosyl-(1 $\rightarrow$ 4)]- β -D-galactopyranosyl-(1 $\rightarrow$ 4)- β -D-glucopyranoside (6a):

To a solution of **22** (12 mg, 0.0065 mmol) in dry MeOH/THF (3:2, 2 mL) was added NaOMe in MeOH (4 M, 48 μ L) at 0 °C. After the solution was stirred at rt for 2 days, the reaction mixture was neutralized with Dowex 50W (H^+) resin, filtered and concentrated under reduced pressure. The product was purified by silica gel column chromatography to give **6a** as a gummy solid (6 mg, 71%). TLC: R_f = 0.2 ($CHCl_3$ /MeOH 1:1). 1H NMR (600 MHz, $CD_3OD:CDCl_3$ 3:2): δ 5.66 (ddd, J = 14.2, 6.7 Hz, 1H, =CH-), 5.42 (ddt, J = 15.3, 7.8, 1.5 Hz, 1H, -CH=), 4.84 (d, J = 8.5 Hz, 1H, anomeric), 4.48 (d, J = 8.4 Hz, 1H, anomeric), 4.30 (d, J = 5.7 Hz, 1H, anomeric), 4.26 (d, J = 7.8 Hz, 1H, anomeric), 4.25 (d, J = 2.1 Hz, 1H), 4.20 (dd, J = 9.9, 3.9 Hz, 1H), 4.06 (t, J = 8.0 Hz, 1H), 3.99 (dd, J = 10.6, 8.4 Hz, 1H), 3.97 – 3.91 (m, 2H), 3.90 – 3.77 (m, 6H), 3.75 (dd, J = 7.5, 3.9 Hz, 1H), 3.73 – 3.67 (m, 2H), 3.64 – 3.59 (m, 2H), 3.57 – 3.46 (m, 8H), 3.38 – 3.34 (m, 1H), 3.31 – 3.27 (m, 1H), 2.14 (t, J = 7.7 Hz, 2H), 2.01 (s, 3H), 1.99 (s, 3H), 1.64 – 1.48 (m, 3H), 1.38 – 1.20 (m, 53H), 0.86 (t, J = 7.0 Hz, 6H). $^{13}C\{^1H\}$ NMR (150 MHz, $CD_3OD:CDCl_3$ 3:2): δ 175.3, 174.4, 134.9, 130.3, 104.7, 104.4, 103.7, 102.9, 84.1, 80.2, 78.6, 78.3, 78.1, 76.1, 76.0, 75.7, 75.4, 74.9, 74.1, 73.3, 73.0, 72.5, 70.5, 69.3, 69.0, 62.4, 61.3, 60.5, 55.0, 52.6, 37.0, 33.0, 32.6, 32.5, 30.3, 30.3, 30.3, 30.3, 30.3, 30.2, 30.2, 30.1, 30.0, 30.0, 30.0, 29.9, 29.9, 27.6, 26.6, 23.3, 23.1, 23.0, 14.3. HRMS (ESI-TOF) m/z : $[M + NH_4]^+$ Calcd. for $C_{64}H_{121}N_4O_{23}$ 1313.8416; Found 1313.8451.

(2*S*,3*R*,*E*)-2-Octadecanamido-3-(pivaloyloxy)hexadec-4-en-1-yl 3,4,6-tri-*O*-acetyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)- β -D-galactopyranosyl-(1 $\rightarrow$ 3)-[3,4,6-tri-*O*-acetyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)- β -D-galactopyranosyl-(1 $\rightarrow$ 4)]-2,6-di-*O*-acetyl- β -D-galactopyranosyl-(1 $\rightarrow$ 4)-2,3,6-tri-*O*-acetyl- β -D-glucopyranoside (21*): Compound **21*** (63 mg, 92%, a white solid) was synthesized from **18** (63 mg, 0.032 mmol) and **19** by the same procedure and conditions employed for the synthesis of **21**. TLC: R_f = 0.4 (Hexane/EtOAc 2:3).

^1H NMR (600 MHz, CDCl_3): δ 6.12 (d, $J = 9.9$ Hz, 1H, -NH), 5.75 (dt, $J = 14.4, 6.8$ Hz, 1H, =CH-), 5.62 (d, $J = 9.3$ Hz, 1H, -NH), 5.40 (d, $J = 2.5$ Hz, 1H), 5.37 – 5.28 (m, 3H), 5.26 – 5.18 (m, 2H), 5.14 – 5.09 (m, 3H), 5.02 (d, $J = 11.5$ Hz, 1H), 4.98 – 4.91 (m, 2H), 4.91 – 4.84 (m, 2H), 4.62 (d, $J = 12.1$ Hz, 1H, - OCH_2CCl_3), 4.54 (d, $J = 12.6$ Hz, 1H, - OCH_2CCl_3), 4.50 (d, $J = 8.1$ Hz, 1H, anomeric), 4.41– 4.38 (m, 2H), 4.35 – 4.29 (m, 1H), 4.29 – 4.16 (m, 5H), 4.18 – 4.10 (m, 2H), 4.09 – 4.02 (m, 3H), 3.96 – 3.86 (m, 3H), 3.86 – 3.78 (m, 1H), 3.69 – 3.65 (m, 2H), 3.71 – 3.59 (m, 1H), 3.58 – 3.52 (m, 1H), 3.48 (dd, $J = 9.7, 4.4$ Hz, 1H), 2.20 (s, 3H), 2.18 (s, 3H), 2.12 (bs, 5H, - CH_3 and - $\text{CHCH}_2\text{CO-}$), 2.10 (s, 3H), 2.09 (s, 3H), 2.06 (s, 3H), 2.04 (s, 3H), 2.03 (s, 3H), 2.02 (s, 3H), 2.01 (s, 3H), 1.98 (s, 3H), 1.60 – 1.53 (m, 2H), 1.34 – 1.22 (m, 50H), 1.16 (s, 9H), 0.87 (t, $J = 7.0$ Hz, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3): δ 176.8, 172.5, 170.9, 170.8, 170.5, 170.5, 170.2, 170.2, 170.1, 170.1, 170.0, 169.7, 168.2, 155.3, 154.4, 137.1, 124.8, 103.0, 100.7, 100.7, 100.3, 96.5, 95.3, 79.7, 74.9, 74.2, 72.9, 72.9, 72.4, 72.0, 71.4, 71.3, 70.9, 70.8, 69.9, 68.3, 67.6, 67.6, 67.5, 66.5, 66.3, 63.2, 62.1, 61.4, 60.9, 55.9, 52.9, 52.1, 52.0, 50.3, 38.7, 36.8, 36.8, 32.2, 31.9, 29.7, 29.6, 29.5, 29.5, 29.4, 29.3, 29.1, 29.0, 27.0, 25.7, 22.6, 20.8, 20.8, 20.8, 20.7, 20.6, 20.6, 20.5, 20.4, 14.1. HRMS (ESI-TOF) m/z : $[\text{M} + \text{NH}_4]^+$ Calcd. for $\text{C}_{91}\text{H}_{145}\text{Cl}_6\text{N}_4\text{O}_{37}$ 2099.7699; Found 2099.7773.

(2*S*,3*R*,*E*)-2-Octadecanamido-3-(pivaloyloxy)hexadec-4-en-1-yl 2-actamino-3,4,6-tri-*O*-acetyl-2-deoxy- β -D-galactopyranosyl-(1 $\rightarrow$ 3)-[2-actamino-3,4,6-tri-*O*-acetyl-2-deoxy- β -D-galactopyranosyl-(1 $\rightarrow$ 4)]-2,6-di-*O*-acetyl- β -D-galactopyranosyl-(1 $\rightarrow$ 4)-2,3,6-tri-*O*-acetyl- β -D-glucopyranoside (22*): Compound **22*** (12.5 mg, 80%, a white solid) was synthesized from **21*** (18 mg, 0.0065) by the same procedure and conditions employed for the synthesis of **22**. TLC: $R_f = 0.25$ (EtOAc). ^1H NMR (600 MHz, CDCl_3): δ 6.74 (d, $J = 8.4$ Hz, 1H, -NH), 6.06 (d, $J = 7.7$ Hz, 1H, -NH), 5.75 (ddt, $J = 14.2, 6.8$ Hz, 1H, =CH-), 5.61 (d, $J = 9.3$ Hz, 1H, -NH), 5.54 – 5.48 (m, 1H), 5.43 – 5.30 (m, 6H), 5.21 (t, $J = 7.3$ Hz, 1H), 5.18 – 5.09 (m, 2H), 4.94 (dd, $J = 9.9, 8.0$ Hz, 1H), 4.88 (dd, $J = 9.6, 7.9$ Hz, 1H), 4.75 (d, $J = 8.1$ Hz, 1H), 4.43 – 4.37 (m, 2H), 4.36 – 4.29 (m, 1H), 4.28 – 4.21 (m, 2H), 4.20 (m, 4H), 4.10 – 4.01 (m, 2H), 3.93 – 3.86 (m, 3H), 3.81 – 3.76 (m, 2H), 3.71 (td, $J = 9.7, 3.9$ Hz, 1H), 3.66 (dd, $J = 10.0, 3.0$ Hz, 1H), 3.61 (bt, $J = 5.7$ Hz, 1H), 3.57 (dq, $J = 7.7, 3.1$ Hz, 1H), 3.49 (dd, $J = 9.8, 4.3$ Hz, 1H), 2.18 (s, 3H), 2.18 (s, 3H), 2.12 (bs, 5H, - CH_3 and - $\text{CHCH}_2\text{CO-}$), 2.10 (s, 3H), 2.08 (s, 3H), 2.08 (s, 3H), 2.05 (s, 3H), 2.03 (brs, $3 \times 3\text{H}$), 2.01 (s, 3H), 2.00 (s, 3H), 1.91 (s, 3H), 1.61 – 1.52 (m, 2H), 1.34 – 1.21 (m, 50H), 1.16 (s, 9H),

0.87 (t, $J = 7.0$ Hz, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3): δ 172.6, 171.9, 171.0, 170.8, 170.7, 170.6, 170.5, 170.4, 170.4, 170.3, 170.0, 169.8, 168.9, 137.2, 124.9, 101.5, 100.7, 100.2, 99.8, 78.4, 74.9, 73.11, 72.4, 72.2, 72.1, 71.7, 71.2, 71.0, 70.7, 70.0, 68.3, 67.7, 67.7, 66.9, 66.8, 63.3, 62.3, 61.6, 61.1, 52.3, 51.6, 50.5, 38.9, 36.9, 32.4, 32.0, 29.8, 29.7, 29.6, 29.6, 29.5, 29.5, 29.3, 29.1, 27.1, 25.8, 23.5, 23.4, 22.8, 21.0, 21.0, 20.9, 20.9, 20.8, 20.8, 20.7, 20.7, 14.2. HRMS (ESI-TOF) m/z : $[\text{M} + \text{Na}]^+$ Calcd. for $\text{C}_{89}\text{H}_{143}\text{N}_3\text{O}_{35}\text{Na}$ 1836.9394; Found 1836.9383.

(2S,3R,E)-2-Octadecanamido-3-hydroxyhexadec-4-en-1-yl ***2-actamino-2-deoxy- β -D-galactopyranosyl-(1 $\rightarrow$ 3)-[2-actamino-2-deoxy- β -D-galactopyranosyl-(1 $\rightarrow$ 4)]- β -D-***

galactopyranosyl-(1 $\rightarrow$ 4)- β -D-glucopyranoside (6a*): Compound **6a*** (5.7 mg, 68%, a glassy solid) was synthesized from compound **22*** (12 mg, 0.0066 mmol) by the same procedure and conditions employed for the synthesis of **6a**. TLC: $R_f = 0.2$ ($\text{CHCl}_3/\text{MeOH}$ 1:1). ^1H NMR (600 MHz, $\text{CD}_3\text{OD}:\text{CDCl}_3$, 3:2): δ 5.72 – 5.61 (m, 1H, =CH-), 5.42 (dd, $J = 15.3, 7.7$ Hz, 1H, -CH=), 4.84 (d, $J = 8.5$ Hz, 1H, anomeric), 4.48 (d, $J = 8.4$ Hz, 1H, anomeric), 4.37 – 4.29 (m, 1H), 4.26 (d, $J = 7.8$ Hz, 1H, anomeric), 4.25 (bs, 1H), 4.19 (dd, $J = 10.0, 3.8$ Hz, 1H), 4.06 (t, $J = 8.1$ Hz, 1H), 4.01 – 3.91 (m, 3H), 3.90 – 3.78 (m, 6H), 3.76 – 3.66 (m, 4H), 3.66 – 3.58 (m, 3H), 3.56 – 3.46 (m, 7H), 3.38 – 3.35 (m, 1H), 3.30 – 3.28 (m, 1H), 2.14 (t, $J = 7.6$ Hz, 2H), 2.01 (s, 3H), 1.99 (s, 3H), 1.66 – 1.52 (m, 2H), 1.38 – 1.19 (m, 48H), 0.86 (t, $J = 7.0$ Hz, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, $\text{CD}_3\text{OD}:\text{CDCl}_3$, 3:2): δ 175.3, 174.4, 134.9, 130.3, 104.6, 104.4, 103.6, 102.9, 84.1, 80.1, 76.1, 75.9, 75.7, 75.3, 74.8, 74.1, 73.3, 73.0, 72.5, 70.4, 69.2, 69.0, 62.3, 61.2, 60.5, 54.3, 53.9, 53.9, 53.8, 37.0, 33.0, 32.5, 32.5, 30.3, 30.3, 30.2, 30.2, 30.2, 30.1, 30.1, 30.1, 30.0, 30.0, 29.9, 29.9, 29.9, 26.6, 23.2, 23.2, 14.3, 14.3. HRMS (ESI-TOF) m/z : $[\text{M} + \text{NH}_4]^+$ Calcd. for $\text{C}_{62}\text{H}_{117}\text{N}_4\text{O}_{23}\text{H}$ 1285.8103; Found 1285.8127.

(2S,3R)-2-Azido-3-(pivaloyloxy)pent-4-en-1-yl ***3,4,6-tri-O-acetyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)- β -D-glucopyranosyl-(1 $\rightarrow$ 3)-2,6-di-O-acetyl- β -D-***

galactopyranosyl-(1 $\rightarrow$ 4)-2,3,6-tri-O-acetyl- β -D-glucopyranoside (24): After a mixture of **12** (0.362 g, 0.475 mmol), **23** (0.306 g, 0.522 mmol), and flame activated MS 4Å in dry CH_2Cl_2 (40 mL) was stirred at rt for 30 min, NIS (0.160 g, 0.712 mmol) was added at -78 °C, followed by TfOH (4.2 μL , 0.047 mmol). The mixture was stirred at -40 to -30 °C for 2 h, after the

disappearance of **12**. The reaction was quenched with triethyl amine (1 mL). The mixture was diluted with CH₂Cl₂ and filtered through a *Celite* bed. The CH₂Cl₂ layer was washed with saturated Na₂S₂O₃ solution, saturated NaHCO₃ solution, water, and brine sequentially and then dried with Na₂SO₄. Solvent was evaporated in vacuo and the residue was purified by silica gel chromatography to afford **24** (0.219 g, 41%) as an off white solid, as well as **25** (0.238 g, 32%, an off white solid) and recovered **12** (31 mg). **24**: TLC: R_f = 0.3 (Toluene/EtOAc 3:7); ¹H NMR (600 MHz, CDCl₃): δ 5.80 (ddd, *J* = 17.3, 10.5, 6.8 Hz, 1H), 5.55 (d, *J* = 6.7 Hz, 1H), 5.40 – 5.27 (m, 4H), 5.20 (d, *J* = 7.2 Hz, 1H, anomeric), 5.14 (t, *J* = 9.4 Hz, 1H), 5.04 (t, *J* = 9.6 Hz, 1H), 4.99 – 4.89 (m, 1H), 4.81 (brs, 2H), 4.73 (t, *J* = 8.8 Hz, 1H), 4.58 – 4.45 (m, 2H, anomeric), 4.33 (d, *J* = 7.7 Hz, 1H, anomeric), 4.28 (dd, *J* = 11.8, 4.9 Hz, 1H), 4.22 – 4.10 (m, 4H), 4.06 (brs, 1H, -OH), 3.84 (dd, *J* = 10.3, 6.7 Hz, 1H), 3.80 – 3.73 (m, 2H), 3.71 – 3.67 (m, 1H), 3.64 – 3.60 (m, 3H), 3.53 (dd, *J* = 10.3, 5.8 Hz, 1H), 3.50 – 3.46 (m, 1H), 2.10 (s, 3H), 2.10 (s, 3H), 2.08 (s, 3H), 2.08 (s, 3H), 2.06 (s, 3H), 2.05 (s, 3H), 2.02 (s, 3H), 2.01 (s, 3H), 1.22 (s, 9H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 176.9, 171.4, 170.9, 170.7, 170.6, 170.5, 170.3, 169.6, 169.6, 154.6, 131.6, 120.4, 100.7, 100.6, 100.5, 95.8, 75.9, 74.8, 73.7, 73.6, 73.1, 72.4, 72.1, 72.0, 71.3, 68.9, 68.0, 63.3, 63.2, 62.28, 62.1, 56.9, 39.0, 27.1, 21.0, 20.9, 20.9, 20.9, 20.8, 20.8, 20.7, 20.7. HRMS (ESI-TOF) *m/z*: [M+Na]⁺ Calcd. for C₄₇H₆₅Cl₃N₄O₂₇Na 1247.2780; Found 1247.2794. **(2*S*,3*R*)-2-Azido-3-(pivaloyloxy)pent-4-en-1-yl 3,4,6-tri-*O*-acetyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)-β-*D*-glucopyranosyl-(1→3)-[3,4,6-tri-*O*-acetyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)-β-*D*-glucopyranosyl-(1→4)]-2,6-di-*O*-acetyl-β-*D*-galactopyranosyl-(1→4)-2,3,6-tri-*O*-acetyl-β-*D*-glucopyranoside (25)**: TLC: R_f = 0.52 (Toluene/EtOAc 3:7); ¹H NMR (600 MHz, CDCl₃): δ 6.04 (d, *J* = 9.9 Hz, 1H, -NH), 5.85 – 5.70 (m, 1H), 5.46 – 5.28 (m, 3H), 5.25 – 5.21 (m, 3H), 5.15 – 5.09 (m, 4H, (anomeric *H*)), 5.07 – 5.02 (m, 2H), 4.99 (d, *J* = 11.9 Hz, 1H), 4.97 – 4.86 (m, 3H), 4.59 (d, *J* = 12.1 Hz, 1H), 4.55 (d, *J* = 12.2 Hz, 1H), 4.48 – 4.41 (m, 3H, (anomeric 2*H*)), 4.38 (dd, *J* = 12.1, 4.6 Hz, 1H), 4.24 – 4.16 (m, 3H, (anomeric *H*)), 4.17 – 4.09 (m, 2H), 4.08 – 4.04 (m, 2H), 3.85 – 3.82 (m, 2H), 3.81 – 3.75 (m, 1H), 3.72 – 3.65 (m, 2H), 3.67 – 3.59 (m, 3H), 3.57 (dd, *J* = 9.9, 5.4 Hz, 1H), 3.51 (dd, *J* = 8.5, 5.8 Hz, 1H), 2.10 (s, 3H), 2.08 (brs, 9H (3 × 3H)), 2.06 (brs, 9H (3 × 3H)), 2.02 (brs, 9H (3 × 3H)), 1.99 (s, 3H), 1.21 (s, 9H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 176.9, 171.5, 170.9, 170.8, 170.7, 170.6, 170.4, 170.3, 169.6, 169.6, 169.5, 168.3, 155.1, 154.6, 131.6, 120.4, 102.8, 100.7, 100.4, 100.0, 96.5, 95.4, 79.3, 75.0, 74.8, 74.5, 73.8, 73.2, 72.6, 72.1, 72.0, 71.6, 71.1, 70.8, 70.3, 69.2,

68.5, 68.1, 63.3, 63.1, 63.0, 62.3, 62.1, 62.0, 56.7, 55.9, 39.0, 27.2, 20.9, 20.9, 20.8, 20.8, 20.7, 20.7, 20.7. HRMS (ESI-TOF) m/z : $[M+Na]^+$ Calcd. for $C_{62}H_{83}Cl_6N_5O_{36}Na$ 1708.2824; Found 1708.2825.

(2S,3R)-2-Azido-3-(pivaloyloxy)pent-4-en-1-yl 3,4,6-tri-O-acetyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)- β -D-glucopyranosyl-(1 $\rightarrow$ 3)-[3,4,6-tri-O-acetyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)- β -D-galactopyranosyl-(1 $\rightarrow$ 4)]-2,6-di-O-acetyl- β -D-galactopyranosyl-(1 $\rightarrow$ 4)-2,3,6-tri-O-acetyl- β -D-glucopyranoside (26): After a mixture of **24** (0.196 g, 0.160 mmol), **16** (0.272 g, 0.464 mmol), and flame activated MS 4Å in dry CH_2Cl_2 (3 mL) was stirred at rt for 30 min, it was cooled to -78 °C and then NIS (0.140 g, 0.624 mmol) was added, followed by TfOH 2.8 μ L (0.032 mmol). The mixture was stirred at -40 to -30 °C for 2 h until the **16** disappeared. The reaction was quenched with Et_3N (1 mL), and the mixture was diluted with CH_2Cl_2 and filtered through a *Celite* bed. The CH_2Cl_2 layer was washed with saturated aqueous $Na_2S_2O_3$, saturated aqueous $NaHCO_3$, water and brine, and dried with Na_2SO_4 . The solvent was evaporated in vacuo and the residue was purified by silica gel chromatography to afford **26** (0.098 g, 75%), with recovered **24** (0.102 g). **26**: TLC: R_f = 0.52; (Toluene/EtOAc 3:7); 1H NMR (600 MHz, $CDCl_3$): δ 6.17 (d, J = 9.8 Hz, 1H), 5.79 (ddd, J = 17.3, 10.5, 6.8 Hz, 1H), 5.41 (d, J = 2.7 Hz, 1H), 5.38 – 5.29 (m, 3H), 5.24 (t, J = 10.6 Hz, 2H), 5.17 (d, J = 8.7 Hz, 1H), 5.16 – 5.10 (m, 2H), 5.06 (t, J = 9.5 Hz, 1H), 5.00 – 4.84 (m, 3H), 4.67 (d, J = 12.1 Hz, 1H), 4.57 (d, J = 12.5 Hz, 1H), 4.53 (d, J = 8.1 Hz, 1H, anomeric), 4.46 (d, J = 7.9 Hz, 1 H, anomeric), 4.43 (d, J = 11.3 Hz, 1H), 4.32 – 4.11 (m, 8H), 4.06 (dd, J = 11.3, 6.2 Hz, 2H), 3.91 (t, J = 6.5 Hz, 1H), 3.89 – 3.81 (m, 3H), 3.81 – 3.76 (m, 1H), 3.73 – 3.65 (m, 3H), 3.64 – 3.60 (m, 1H), 3.58 (dd, J = 8.7, 4.7 Hz, 1H), 3.55 – 3.51 (m, 1H), 2.19 (s, 3H), 2.11 (s, 3H), 2.09 (s, 3H), 2.08 (brs, 6H (2 $\times$ 3H)), 2.07 (brs, 6H (2 $\times$ 3H)), 2.06 (s, 3H), 2.02 (s, 3H), 2.01 (s, 3H), 1.97 (s, 3H), 1.22 (s, 9H). $^{13}C\{^1H\}$ NMR (150 MHz, $CDCl_3$): δ 176.9, 170.9, 170.9, 170.8, 170.7, 170.6, 170.4, 170.3, 169.9, 169.6, 169.4, 168.4, 155.3, 154.5, 131.5, 120.4, 103.0, 100.7, 100.4, 100.1, 96.5, 95.4, 79.7, 75.1, 75.0, 74.4, 73.8, 73.1, 72.8, 72.6, 72.3, 71.9, 71.7, 71.4, 71.10, 70.1, 69.5, 68.4, 68.0, 66.6, 63.2, 63.0, 62.4, 62.2, 61.0, 55.7, 53.1, 39.0, 29.8, 27.2, 20.9, 20.8, 20.8, 20.7, 20.7, 20.7, 20.7, 20.6, 20.6. HRMS (ESI-TOF) m/z : $[M+Na]^+$ Calcd. for $C_{62}H_{83}Cl_6N_5O_{36}Na$ 1708.2824; Found 1708.2834.

(2*S*,3*R*)-2-Octadecanamido-3-(pivaloyloxy)pent-4-en-1-yl 3,4,6-tri-*O*-acetyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)- β -D-glucopyranosyl-(1 $\rightarrow$ 3)-[3,4,6-tri-*O*-acetyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)- β -D-galactopyranosyl-(1 $\rightarrow$ 4)]-2,6-di-*O*-acetyl- β -D-galactopyranosyl-(1 $\rightarrow$ 4)-2,3,6-tri-*O*-acetyl- β -D-glucopyranoside (27): After PPh₃ (28.7 mg, 0.109 mmol) and water (29.6 μ L, 1.65 mmol) were added to a stirred solution of **26** (92.6 mg, 0.054 mmol) in THF (3 mL), the mixture was heated with stirring at 50 °C using an aluminium heating block until TLC indicated the disappearance of **26**. The solvent was removed under vacuum, and the residue was dissolved in dry dichloromethane (3 mL). Then, EDC (24.1 mg, 0.126 mmol), DMAP (1.3 mg, 0.010 mmol), and stearic acid (35.8 mg, 0.126 mmol) were added at 0 °C under argon, and the mixture was stirred at rt for 12 h. The reaction was quenched with water and the product was extracted with CH₂Cl₂. The organic layer was separated, washed with water, dried over Na₂SO₄ and concentrated. The residue was purified by silica gel column chromatography to afford **27** (92.7 mg, 82%) as a glassy solid. TLC: *R*_f = 0.8 (EtOAc). ¹H NMR (600 MHz, CDCl₃): δ 6.19 (d, *J* = 9.8 Hz, 1H), 5.78 (ddd, *J* = 17.0, 10.6, 6.2 Hz, 1H), 5.67 (d, *J* = 9.2 Hz, 1H), 5.41 – 5.41 (m, 1H), 5.32 – 5.20 (m, 5H), 5.17 (d, *J* = 7.9 Hz, 1H), 5.14 – 5.11 (m, 2H), 5.06 (t, *J* = 9.6 Hz, 1H), 4.96 – 4.91 (m, 2H), 4.90 – 4.85 (m, 1H), 4.66 (d, *J* = 12.0 Hz, 1H), 4.56 (d, *J* = 12.6 Hz, 1H), 4.51 (d, *J* = 8.0 Hz, 1H), 4.43 – 4.34 (m, 3H), 4.27 – 4.14 (m, 7H), 4.08 – 4.01 (m, 2H), 3.96 – 3.83 (m, 4H), 3.75 – 3.64 (m, 3H), 3.64 – 3.60 (m, 1H), 3.56 (dd, *J* = 9.1, 5.1 Hz, 1H), 3.51 (dd, *J* = 9.9, 4.5 Hz, 1H), 2.19 (s, 3H), 2.10 (brs, 8H, (2 $\times$ 3H and 2H -COCH₂-CH₂)), 2.08 (s, 3H), 2.07 (s, 3H), 2.07 (s, 3H), 2.06 (s, 3H), 2.03 (s, 3H), 2.02 (s, 3H), 2.01 (s, 3H), 1.97 (s, 3H), 1.63 – 1.53 (m, 2H), 1.31 – 1.22 (m, 28H), 1.19 (s, 9H), 0.87 (t, *J* = 7.0 Hz, 3H). ¹³C {¹H} NMR (150 MHz, CDCl₃): δ 177.0, 172.8, 170.9, 170.8, 170.6, 170.6, 170.3, 170.2, 169.8, 169.3, 168.3, 155.3, 154.5, 133.3, 118.9, 103.1, 100.9, 100.4, 100.1, 96.5, 95.4, 79.6, 75.1, 74.8, 74.4, 73.1, 73.1, 72.8, 72.6, 72.3, 72.0, 71.5, 71.4, 70.1, 69.5, 68.4, 67.7, 66.6, 63.0, 62.4, 62.2, 61.0, 55.7, 53.1, 50.2, 38.9, 36.9, 32.0, 29.8, 29.8, 29.7, 29.7, 29.6, 29.5, 29.5, 29.4, 27.1, 25.8, 22.8, 20.9, 20.9, 20.9, 20.8, 20.7, 20.7, 20.7, 20.6, 20.6, 14.2. HRMS (ESI-TOF) *m/z*: [M+H]⁺ Calcd. for C₈₀H₁₂₀Cl₆N₃O₃₇ 1928.5705; Found 1928.5688.

(2*S*,3*R*,*E*)-2-Octadecanamido-3-(pivaloyloxy)octadec-4-en-1-yl 3,4,6-tri-*O*-acetyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)- β -D-glucopyranosyl-(1 $\rightarrow$ 3)-[3,4,6-tri-*O*-acetyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)- β -D-galactopyranosyl-(1 $\rightarrow$ 4)]-2,6-di-*O*-acetyl- β -D-

galactopyranosyl-(1→4)-2,3,6-tri-O-acetyl-β-D-glucopyranoside (28): To a solution of **27** (64 mg, 0.033 mmol) and pentadecene-1 **19** (72 μL, 0.265 mmol) in dry CH₂Cl₂ (16 mL) was added catalyst **20** (6.2 mg, 0.009 mmol). The mixture was heated to reflux in an aluminium heating block for 5 days. After every 24 h, another batch of **19** (0.36 μL, 0.132 mmol) and the catalyst (10 mol%) were added. After reaction was completed, 2 drops of DMSO was added at rt, followed by stirring for an additional 2 h. The mixture was concentrated, and the product was purified by silica gel column chromatography to give **28** (62.7 mg, 89%) as a white glassy solid. TLC: R_f = 0.4 (Hex/EtOAc 2:3). ¹H NMR (600 MHz, CDCl₃): δ 6.18 (d, *J* = 9.8 Hz, 1H), 5.75 (dt, *J* = 14.3, 6.8 Hz, 1H), 5.61 (d, *J* = 9.3 Hz, 1H), 5.41 (brs, 1H), 5.33 (dd, *J* = 15.4, 7.5 Hz, 1H), 5.30 – 5.17 (m, 4H), 5.12 (dd, *J* = 11.9, 7.1 Hz, 3H), 5.08 – 5.02 (m, 1H), 4.95 – 4.92 (m, 2H), 4.91 – 4.86 (m, 1H), 4.66 (d, *J* = 12.0 Hz, 1H), 4.56 (d, *J* = 12.6 Hz, 1H), 4.52 (d, *J* = 7.9 Hz, 1H), 4.42 – 4.38 (m, 2H), 4.34 – 4.30 (m, 1H), 4.27 – 4.14 (m, 7H), 4.06 (dd, *J* = 11.2, 6.3 Hz, 1H), 4.02 (dd, *J* = 11.7, 5.1 Hz, 1H), 3.93 – 3.84 (m, 4H), 3.70 – 3.65 (m, 3H), 3.64 – 3.61 (m, 1H), 3.55 (dd, *J* = 8.7, 4.8 Hz, 1H), 3.48 (dd, *J* = 9.8, 4.4 Hz, 1H), 2.20 (s, 3H), 2.10 (brd, 8H, 2 × 3H and 2H -COCH₂-), 2.08 (s, 3H), 2.08 (s, 3H), 2.07 (s, 3H), 2.06 (s, 3H), 2.03 (s, 3H), 2.02 (s, 3H), 2.01 (s, 3H), 1.97 (s, 3H), 1.59 – 1.55 (m, 2H), 1.34 – 1.22 (m, 52H), 1.16 (s, 9H), 0.88 (t, *J* = 7.0 Hz, 6H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 177.0, 172.6, 170.9, 170.8, 170.6, 170.6, 170.3, 170.2, 169.8, 169.3, 168.3, 155.3, 154.5, 137.2, 124.9, 103.2, 100.9, 100.4, 100.2, 96.5, 95.4, 79.7, 75.1, 74.8, 74.5, 73.0, 73.0, 72.8, 72.6, 72.3, 72.0, 71.6, 71.4, 70.0, 69.5, 68.5, 67.7, 66.6, 63.0, 62.4, 62.2, 60.9, 55.7, 53.1, 50.4, 38.9, 37.0, 32.4, 32.0, 29.8, 29.8, 29.8, 29.6, 29.6, 29.5, 29.5, 29.3, 29.1, 27.1, 25.8, 22.8, 20.9, 20.9, 20.8, 20.7, 20.7, 20.7, 20.7, 20.6, 14.2. HRMS (ESI-TOF) *m/z*: [M+NH₄]⁺ Calcd. for C₉₃H₁₄₅Cl₆N₃O₃₇NH₄ 2125.8020; Found 2125.7974.

(2*S*,3*R*,*E*)-2-Octadecanamido-3-(pivaloyloxy)octadec-4-en-1-yl 2-actamino-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyl-(1→3)-[2-actamino-3,4,6-tri-O-acetyl-2-deoxy-β-D-galactopyranosyl-(1→4)]-2,6-di-O-acetyl-β-D-galactopyranosyl-(1→4)-2,3,6-tri-O-acetyl-β-D-glucopyranoside (29): To a solution of **28** (27 mg, 0.012 mmol) in AcOH and THF (2:3, 2 ml) was added activated Zn (83.6 mg, 1.28 mmol). After the mixture was stirred at rt for 12 h, it was filtered through a *Celite* pad and the solution was concentrated under reduced pressure. The crude product was dissolved in pyridine (1 mL) and Ac₂O (0.7 mL) at 0 °C, and the solution was stirred at rt overnight. After completion of the reaction, the solution was concentrated under vacuum and

the product was purified by silica gel column chromatography to give **29** (16 mg, 72%) as yellow syrup. TLC: R_f = 0.25 (EtOAc). ^1H NMR (600 MHz, CDCl_3): δ 6.89 (d, J = 8.2 Hz, 1H), 5.99 (d, J = 7.6 Hz, 1H), 5.75 (dt, J = 14.3, 6.8 Hz, 1H), 5.62 (d, J = 9.3 Hz, 1H), 5.57 (t, J = 9.8 Hz, 1H), 5.46 – 5.38 (m, 2H), 5.41 – 5.30 (m, 2H), 5.21 (t, J = 7.4 Hz, 1H), 5.13 (t, J = 9.5 Hz, 1H), 5.04 (t, J = 9.6 Hz, 1H), 4.93 (dd, J = 9.9, 8.0 Hz, 1H), 4.88 (dd, J = 9.7, 7.9 Hz, 1H), 4.71 (d, J = 8.1 Hz, 1H), 4.44 – 4.37 (m, 2H), 4.36 – 4.27 (m, 1H), 4.27 – 4.21 (m, 3H), 4.19 (t, J = 3.9 Hz, 2H), 4.14 (d, J = 2.6 Hz, 1H), 4.10 (dd, J = 11.7, 6.8 Hz, 1H), 4.07 – 4.00 (m, 2H), 3.94 – 3.87 (m, 3H), 3.74 – 3.63 (m, 5H), 3.61 (t, J = 5.9 Hz, 1H), 3.55 (ddd, J = 9.6, 5.3, 1.8 Hz, 1H), 3.49 (dd, J = 9.8, 4.3 Hz, 1H), 2.18 (s, 3H), 2.10 (s, 3H), 2.09 (s, 3H), 2.08 (brs, 5H, (1 $\times$ 3H and 2H -COCH₂-CH₂)), 2.08 (s, 3H), 2.06 (s, 3H), 2.06 (s, 3H), 2.05 (s, 3H), 2.03 (s, 6H, (2 $\times$ 3H)), 2.02 (s, 3H), 1.97 (s, 3H), 1.93 (s, 3H), 1.62 – 1.50 (m, 1H), 1.34 – 1.22 (m, 52H), 1.16 (s, 9H), 0.87 (t, J = 7.0 Hz, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3): δ 177.0, 172.6, 171.8, 171.1, 170.8, 170.8, 170.7, 170.6, 170.5, 170.5, 170.3, 169.9, 169.8, 169.5, 168.8, 137.2, 124.9, 101.8, 100.8, 100.2, 99.2, 78.4, 74.7, 73.1, 73.0, 72.5, 72.4, 72.1, 72.0, 71.6, 71.2, 70.7, 69.7, 68.4, 67.7, 66.9, 63.1, 62.4, 62.2, 61.0, 54.9, 52.1, 50.5, 38.9, 37.0, 32.4, 32.0, 29.8, 29.8, 29.8, 29.6, 29.6, 29.5, 29.5, 29.3, 29.1, 27.1, 25.8, 23.5, 23.2, 22.8, 20.9, 20.9, 20.9, 20.9, 20.8, 20.8, 20.7, 20.7, 20.7, 20.6, 14.2. HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd. for $\text{C}_{91}\text{H}_{148}\text{N}_3\text{O}_{35}$ 1842.9888; Found 1865.9870.

(2*S*,3*R*,*E*)-2-Octadecanamido-3-hydroxyoctadec-4-en-1-yl **2-actamino-2-deoxy- β -D-glucopyranosyl-(1 $\rightarrow$ 3)-[2-actamino-2-deoxy- β -D-galactopyranosyl-(1 $\rightarrow$ 4)]- β -D-**

galactopyranosyl-(1 $\rightarrow$ 4)- β -D-glucopyranoside (6, LcGg4): To a solution of **29** (15 mg, 0.008 mmol) in dry MeOH and THF (2 mL) was added NaOMe in MeOH (4 M, 48 μL) at 0 $^\circ\text{C}$. After the solution was stirred at rt for 2 d, the reaction was neutralized with Dowex 50W (H^+) resin, and the solution was filtered and concentrated under reduced pressure. The product was purified by silica gel column chromatography to give **6** as a gummy solid (8.2 mg, 77 %). TLC: R_f = 0.2 ($\text{CHCl}_3/\text{MeOH}$ 1:1). ^1H NMR (600 MHz, $\text{CD}_3\text{OD}:\text{CDCl}_3$, 1:1): δ 5.66 (dt, J = 14.0, 6.7 Hz, 1H), 5.42 (dd, J = 15.3, 7.7 Hz, 1H), 4.84 (d, J = 8.5 Hz, 1H, anomeric), 4.47 (d, J = 8.4 Hz, 1H, anomeric), 4.31 – 4.27 (m, 1H), 4.25 (d, J = 7.8 Hz, 1H, anomeric), 4.22 (brs, 1H), 4.19 (dd, J = 10.0, 3.8 Hz, 1H), 4.05 (t, J = 7.9 Hz, 1H), 4.00 – 3.92 (m, 2H), 3.92 – 3.89 (m, 2H), 3.87 – 3.77 (m, 5H), 3.76 – 3.68 (m, 2H), 3.61 – 3.54 (m, 3H), 3.54 – 3.44 (m, 7H), 3.36 – 3.33 (m, 2H), 3.30 – 3.26 (m, 1H), 3.25 – 3.17 (m, 2H), 2.17 – 2.11 (m, 2H), 1.99 (s, 3H), 1.98 (s, 3H), 1.64 – 1.50

(m, 3H), 1.36 – 1.18 (m, 51H), 0.85 (t, $J = 7.0$ Hz, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, $\text{CD}_3\text{OD}:\text{CDCl}_3$, 1:1): δ 175.2, 174.3, 173.8, 134.9, 130.0, 104.4, 104.3, 103.5, 102.5, 83.9, 80.0, 76.6, 76.0, 75.9, 75.9, 75.5, 75.2, 74.6, 73.9, 73.0, 72.4, 72.2, 70.3, 69.1, 68.8, 62.8, 62.2, 61.2, 60.2, 59.5, 56.6, 54.3, 53.8, 49.5, 36.9, 32.9, 32.4, 32.4, 30.2, 30.2, 30.1, 30.1, 30.1, 30.1, 30.0, 29.9, 29.8, 29.8, 29.8, 26.5, 23.1, 23.01, 23.0, 14.3. HRMS (ESI-TOF) m/z : $[\text{M}+\text{NH}_4]^+$ Calcd. for $\text{C}_{64}\text{H}_{117}\text{N}_3\text{O}_{23}\text{NH}_4$ 1313.8416; Found 1313.8421.

(2*S*,3*R*)-2-(tert-Butoxycarbonyl)amino-3-(pivaloyloxy)pent-4-en-1-yl 3,4,6-tri-*O*-acetyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)- β -D-galactopyranosyl-(1 $\rightarrow$ 3)-[3,4,6-tri-*O*-acetyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)- β -D-galactopyranosyl-(1 $\rightarrow$ 4)]-2,6-di-*O*-acetyl- β -D-galactopyranosyl-(1 $\rightarrow$ 4)-2,3,6-tri-*O*-acetyl- β -D-glucopyranoside (30): A mixture of PPh_3 (62.5 mg, 0.238 mmol), water (22 μL , 1.19 mmol), and **17** (201 mg, 0.119 mmol) in THF (4 mL) was stirred at 50 $^\circ\text{C}$ using an aluminium heating block until TLC indicated the complete consumption of **17**. The solvents were removed under reduced pressure, and the residue was dissolved in dry CH_2Cl_2 (6 mL). After the solution was cooled to 0 $^\circ\text{C}$, Boc_2O (38.8 mg, 0.178 mmol), DMAP (0.7 mg, 0.006 mmol), and DIPEA (75.4 μL , 0.355 mmol) were added under argon. After stirring at rt for 12 h, the solvent was removed in *vacuo* and the residue was purified by silica gel column chromatography to afford **30** (172 mg, 82%) as a white solid. TLC: $R_f = 0.4$ (EtOAc/Hex 3:2). ^1H NMR (600 MHz, CDCl_3): δ 6.10 (d, $J = 9.9$ Hz, 1H, -NH), 5.78 (ddd, $J = 16.9, 10.6, 6.1$ Hz, 1H, =CH-), 5.41 (d, $J = 3.0$ Hz, 1H), 5.37 – 5.33 (m, 1H), 5.31 – 5.21 (m, 4H), 5.19 – 5.06 (m, 3H), 5.05 – 4.99 (m, 1H), 4.98 – 4.86 (m, 3H), 4.70 (d, $J = 9.4$ Hz, 1H, - OCH_2CCl_3), 4.63 (d, $J = 12.1$ Hz, 1H, - OCH_2CCl_3), 4.55 (d, $J = 12.6$ Hz, 1H, - OCH_2CCl_3), 4.50 (d, $J = 8.2$ Hz, 1H, anomeric), 4.40 (bd, $J = 8.3$ Hz, 2H, anomeric 1H), 4.31 – 4.17 (m, 4H), 4.17 – 4.11 (m, 2H), 4.10 – 3.98 (m, 5H), 3.94 (dd, $J = 10.0, 3.2$ Hz, 1H), 3.92 – 3.89 (m, 2H), 3.87 – 3.76 (m, 1H), 3.70 – 3.64 (m, 2H), 3.63 – 3.60 (m, 1H), 3.58 – 3.54 (m, 1H), 3.49 (dd, $J = 10.0, 4.8$ Hz, 1H), 2.20 (s, 3H), 2.18 (s, 3H), 2.12 (s, 3H), 2.11 (s, 3H), 2.09 (s, 3H), 2.06 (brs, $2 \times 3\text{H}$), 2.04 (s, 3H), 2.02 (s, 3H), 2.01 (s, 3H), 1.98 (s, 3H), 1.41 (s, 9H), 1.19 (s, 9H). $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3): δ 177.0, 170.9, 170.7, 170.6, 170.6, 170.4, 170.4, 170.2, 169.9, 169.8, 169.8, 168.3, 155.3, 154.5, 133.1, 118.7, 103.2, 101.2, 100.8, 100.4, 96.6, 95.4, 79.9, 79.8, 75.1, 75.0, 74.4, 73.2, 73.0, 72.6, 72.1, 71.5, 71.4, 71.3, 71.0, 70.9, 70.1, 68.6, 68.4, 66.6, 66.5, 63.3, 62.2, 61.5, 61.0, 53.1, 52.1, 52.1, 38.9, 28.4, 27.1,

21.0, 20.9, 20.9, 20.8, 20.7, 20.7, 20.7, 20.7, 20.7, 20.7, 20.6. HRMS (ESI-TOF) m/z : $[M + Na]^+$ Calcd. for $C_{67}H_{93}Cl_6N_3O_{38}Na$ 1782.3554; Found 1782.3531.

(2*S*,3*R*,*E*)-2-(tert-Butoxycarbonyl)amino-3-(pivaloyloxy)octadec-4-en-1-yl 3,4,6-tri-*O*-acetyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)- β -D-galactopyranosyl-(1 $\rightarrow$ 3)-[3,4,6-tri-*O*-acetyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)- β -D-galactopyranosyl-(1 $\rightarrow$ 4)]-2,6-di-*O*-acetyl- β -D-galactopyranosyl-(1 $\rightarrow$ 4)-2,3,6-tri-*O*-acetyl- β -D-glucopyranoside (31): Compound **31** (155 mg, 82%, a brownish solid) was synthesized from **30** (170 mg, 0.096 mmol) by the same procedure and conditions employed for the synthesis of **21**. TLC: R_f = 0.5 (EtOAc/Hexane, 3/2). 1H NMR (600 MHz, $CDCl_3$): δ 6.12 (d, J = 10.0 Hz, 1H, -NH), 5.78 (dt, J = 14.1, 6.6 Hz, 1H, =CH-), 5.43 (d, J = 3.0 Hz, 1H), 5.41 – 5.29 (m, 3H), 5.25 (d, J = 8.6 Hz, 1H), 5.22 – 5.19 (m, 1H), 5.18 – 5.10 (m, 3H), 5.05 (dd, J = 11.4, 3.0 Hz, 1H), 5.01 – 4.90 (m, 3H), 4.69 (d, J = 9.4 Hz, 1H, -OCH₂CCl₃), 4.65 (d, J = 12.1 Hz, 1H, -OCH₂CCl₃), 4.57 (d, J = 12.6 Hz, 1H, -OCH₂CCl₃), 4.53 (d, J = 8.1 Hz, 1H, anomeric), 4.42 (broad d, J = 7.7 Hz, 2H, anomeric 1H), 4.31 – 4.20 (m, 5H), 4.20 – 4.14 (m, 2H), 4.13 – 4.03 (m, 3H), 4.01 – 3.90 (m, 4H), 3.89 – 3.79 (m, 1H), 3.74 – 3.67 (m, 2H), 3.66 – 3.62 (m, 1H), 3.61 – 3.56 (m, 1H), 3.49 (dd, J = 9.7, 4.4 Hz, 1H), 2.23 (s, 3H), 2.21 (s, 3H), 2.15 (s, 3H), 2.13 (s, 3H), 2.11 (s, 3H), 2.09 (s, 3H), 2.08 (s, 3H), 2.06 (s, 3H), 2.04 (s, 3H), 2.04 (s, 3H), 2.01 (s, 3H), 1.43 (s, 9H), 1.39 – 1.24 (m, 24H), 1.18 (s, 9H), 0.90 (t, J = 7.0 Hz, 3H). $^{13}C\{^1H\}$ NMR (150 MHz, $CDCl_3$): δ 176.9, 170.9, 170.7, 170.6, 170.6, 170.4, 170.4, 170.2, 169.9, 169.8, 168.4, 155.4, 154.5, 137.1, 124.6, 103.2, 101.2, 100.8, 100.5, 96.6, 95.4, 79.9, 79.6, 75.1, 75.0, 74.4, 73.2, 73.0, 72.6, 72.1, 71.5, 71.4, 71.3, 71.1, 70.9, 70.1, 68.6, 68.4, 66.6, 66.5, 63.3, 62.3, 61.5, 61.0, 53.1, 52.2, 52.2, 42.8, 38.8, 32.4, 32.0, 29.8, 29.7, 29.7, 29.7, 29.6, 29.4, 29.3, 29.0, 28.4, 27.1, 22.8, 21.0, 20.9, 20.9, 20.8, 20.7, 20.7, 20.7, 20.6, 14.2. HRMS (ESI-TOF) m/z : $[M + Na]^+$ Calcd. for $C_{80}H_{119}Cl_6N_3O_{38}Na$ 1966.5484; Found 1966.5475.

(2*S*,3*R*,*E*)-2-(tert-Butoxycarbonyl)amino-3-(pivaloyloxy)octadec-4-en-1-yl 2-acetamido-3,4,6-tri-*O*-acetyl-2-deoxy- β -D-galactopyranosyl-(1 $\rightarrow$ 3)-[2-acetamido-3,4,6-tri-*O*-acetyl-2-deoxy- β -D-galactopyranosyl-(1 $\rightarrow$ 4)]-2,6-di-*O*-acetyl- β -D-galactopyranosyl-(1 $\rightarrow$ 4)-2,3,6-tri-*O*-acetyl- β -D-glucopyranoside (32): Freshly activated Zn dust (474 mg, 7.25 mmol) was added to a solution of **31** (141 mg, 0.0723 mmol) in AcOH and THF (2:3, 5 mL), and the mixture was stirred at rt for 12 h until TLC indicated the disappearance of **31**. The mixture was filtered through a *Celite* pad

and the solution was concentrated under reduced pressure. The residue was dissolved in Ac₂O (3 mL) and Et₃N (50 μ L, 0.362 mmol), and the solution was stirred at rt for 8 h. The solution was concentrated and the product was purified by silica gel column chromatography to give **32** (91 mg, 74%) as a white solid. TLC: R_f = 0.2 (EtOAc). ¹H NMR (600 MHz, CDCl₃): δ 6.74 (d, J = 8.3 Hz, 1H, -NH), 6.08 (d, J = 7.5 Hz, 1H, -NH), 5.76 (dt, J = 14.0, 6.7 Hz, 1H, =CH-), 5.55 (d, J = 9.7 Hz, 1H, -NH), 5.41 - 5.32 (m, 6H), 5.18 (t, J = 7.1 Hz, 1H), 5.16 - 5.10 (m, 1H), 5.00 - 4.87 (m, 2H), 4.77 (d, J = 8.0 Hz, 1H, anomeric), 4.66 (d, J = 9.5 Hz, 1H, anomeric), 4.40 (broad d, J = 8.4 Hz, 2H, anomeric), 4.27 - 4.22 (m, 3H), 4.19 - 4.03 (m, 7H), 4.00 - 3.94 (m, 1H), 3.92-3.88 (m, 3H), 3.80 - 3.69 (m, 3H), 3.66 (dd, J = 10.0, 2.9 Hz, 1H), 3.63 - 3.60 (m, 1H), 3.60 - 3.54 (m, 1H), 3.47 (dd, J = 9.9, 4.5 Hz, 1H), 2.27 - 2.16 (2s, 6H), 2.12 (s, 3H), 2.10 (s, 3H), 2.08 (broad s, 2 $\times$ 3H), 2.05 (broad s, 2 $\times$ 3H), 2.03 (2s, 2 $\times$ 3H), 2.01 (s, 3H), 2.00 (s, 3H), 1.91 (s, 3H), 1.41 (s, 9H), 1.34 - 1.21 (m, 24H), 1.16 (s, 9H), 0.87 (t, J = 7.0 Hz, 3H). ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 176.9, 171.9, 171.0, 170.8, 170.7, 170.7, 170.6, 170.4, 170.4, 170.3, 170.0, 169.7, 168.9, 137.1, 124.6, 101.5, 101.1, 100.3, 99.7, 79.6, 78.4, 75.0, 73.2, 73.0, 72.4, 72.3, 72.2, 71.5, 71.2, 71.0, 70.7, 70.0, 68.5, 68.5, 68.2, 66.9, 66.8, 63.3, 62.3, 61.6, 61.1, 52.4, 52.2, 51.7, 38.9, 32.4, 32.0, 29.8, 29.7, 29.7, 29.7, 29.6, 29.4, 29.3, 29.0, 28.4, 27.1, 23.5, 23.4, 22.8, 21.0, 21.0, 20.9, 20.9, 20.8, 20.8, 20.8, 20.7, 20.7. HRMS (ESI-TOF) m/z : [M + Na]⁺ Calcd. for C₇₈H₁₂₁N₃O₃₆Na 1698.7622; Found. 1698.7604.

(2S,3R,E)-2-{11-[(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino]undecanamido}-3-(pivaloyloxy)octadec-4-en-1-yl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy- β -D-galactopyranosyl-(1 $\rightarrow$ 3)-[2-acetamido-3,4,6-tri-O-acetyl-2-deoxy- β -D-galactopyranosyl-(1 $\rightarrow$ 4)]-2,6-di-O-acetyl- β -D-galactopyranosyl-(1 $\rightarrow$ 4)-2,3,6-tri-O-acetyl- β -D-glucopyranoside (34**):** TFA (68 μ L, 0.894 mmol) was added to a stirred solution of **32** (30 mg, 0.017 mmol) in CH₂Cl₂ (4 mL) at rt, and the mixture was stirred until TLC indicated the disappearance of **32**. The solvent was removed under reduced pressure, and the residue was dissolved in dry CH₂Cl₂ (3 mL). Then, EDC (15.5 mg, 0.081 mmol), DMAP (2 mg, 0.017 mmol), and 11-[(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino]undecanoic acid **33** (29.5 mg, 0.081 mmol) were added at 0 °C, which was followed by DIPEA (52 μ L, 0.243). The mixture was stirred under argon at rt for 12 h. After completion of the reaction, water was added in the reaction mixture. The organic layer was separated and washed with saturated NaHCO₃ solution, water, and brine and then dried over Na₂SO₄. The solvent was

removed in vacuo and the residue was purified by silica gel column chromatography to afford **34** (29 mg, 83%) as a yellowish brown solid. TLC: R_f = 0.7 (EtOAc/MeOH, 6:1). ^1H NMR (600 MHz, CDCl_3): δ 8.52 (d, J = 8.6 Hz, 1H), 6.85 (d, J = 8.5 Hz, 1H, -NH), 6.60 (bs, 1H, -NH), 6.21 (dd, J = 8.7, 2.9 Hz, 1H), 6.12 (d, J = 7.9 Hz, 1H, -NH), 5.76 (dt, J = 14.5, 7.0 Hz, 1H, =CH-), 5.68 (d, J = 9.2 Hz, 1H, -NH), 5.42 (d, J = 3.1 Hz, 1H), 5.40 – 5.30 (m, 4H), 5.24 (t, J = 7.2 Hz, 1H), 5.15 (t, J = 9.4 Hz, 1H), 4.96 (dd, J = 9.9, 8.0 Hz, 1H), 4.89 (dd, J = 9.7, 7.9 Hz, 1H), 4.75 (d, J = 8.1 Hz, 1H), 4.44 – 4.41 (m, 2H), 4.36 – 4.32 (m, 1H), 4.30 – 4.24 (m, 3H), 4.24 – 4.12 (m, 4H), 4.11 – 4.03 (m, 2H), 4.00 – 3.83 (m, 4H), 3.74 (t, J = 9.5 Hz, 1H), 3.70 (dd, J = 10.1, 3.0 Hz, 1H), 3.67 – 3.62 (m, 1H), 3.62 – 3.56 (m, 2H), 3.54 – 3.52 (m, 3H), 2.36 (t, J = 7.4 Hz, 1H), 2.21 (s, 3H), 2.20 (s, 3H), 2.13 (s, 3H), 2.12 (s, 3H), 2.10 (s, 3H), 2.10 (s, 3H), 2.07 (s, 3H), 2.06 – 2.04 (s, 3 $\times$ 3H), 2.03 (s, 3H), 2.02 (s, 3H), 1.95 (s, 3H), 1.85 – 1.80 (m, 2H), 1.68 – 1.61 (m, 2H), 1.49 – 1.46 (m, 2H), 1.42 – 1.23 (m, 37H), 1.18 (s, 9H), 0.89 (t, J = 7.0 Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3): δ 176.9, 172.5, 171.8, 171.0, 170.7, 170.5, 170.4, 170.3, 170.3, 170.1, 169.9, 169.7, 168.7, 144.3, 143.9, 136.9, 136.6, 136.6, 124.8, 100.6, 100.1, 99.9, 98.5, 78.4, 74.7, 72.9, 72.3, 72.0, 72.0, 71.6, 71.0, 70.9, 70.5, 68.3, 67.5, 66.7, 66.6, 63.1, 61.5, 60.9, 51.8, 51.0, 50.5, 44.0, 43.9, 38.7, 36.7, 33.5, 32.2, 31.9, 29.7, 29.6, 29.5, 29.3, 29.1, 29.1, 29.1, 29.1, 29.0, 29.0, 29.0, 29.0, 28.8, 28.4, 27.0, 26.8, 25.5, 24.6, 23.3, 23.1, 22.6, 20.8, 20.8, 20.8, 20.7, 20.6, 20.5, 14.1. HRMS (ESI-TOF) m/z : $[\text{M} + \text{Na}]^+$ Calcd. for $\text{C}_{90}\text{H}_{135}\text{N}_7\text{O}_{38}\text{Na}$ 1944.8739; Found. 1944.8776.

(2*S*,3*R*,*E*)-2-{11-[(7-nitrobenzo[*c*][1,2,5]oxadiazol-4-yl)amino]undecanamido}-3-hydroxyoctadec-4-en-1-yl 2-acetamido-2-deoxy- β -D-galactopyranosyl-(1 $\rightarrow$ 3)-[2-acetamido-2-deoxy- β -D-galactopyranosyl-(1 $\rightarrow$ 4)]- β -D-galactopyranosyl-(1 $\rightarrow$ 4)- β -D-glucopyranoside (35**):**

Compound **35** (8.1 mg, 85%, a yellowish brown solid) was synthesized from **34** (14 mg, 0.007 mmol) by the same procedure and reaction conditions employed for the synthesis of **6a**. TLC: R_f = 0.3 ($\text{CHCl}_3/\text{MeOH}$ 1:1). ^1H NMR (600 MHz, $\text{CD}_3\text{OD}:\text{CDCl}_3$, 3:2): δ 8.50 (d, J = 8.0 Hz, 1H), 6.23 (d, J = 7.6 Hz, 1H), 5.66 (dt, J = 14.3, 6.7 Hz, 1H, =CH-), 5.42 (dd, J = 15.3, 7.7 Hz, 1H, -CH=), 4.83 (d, J = 8.5 Hz, 1H, anomeric), 4.48 (d, J = 8.3 Hz, 1H, anomeric), 4.30 (d, J = 6.9 Hz, 1H, anomeric), 4.26 – 4.22 (m, 4H), 4.18 (dd, J = 9.8, 3.8 Hz, 1H), 4.06 (t, J = 7.8 Hz, 1H), 4.01 – 3.90 (m, 3H), 3.89 – 3.76 (m, 6H), 3.74 (dd, J = 9.6, 3.7 Hz, 1H), 3.70 (td, J = 12.2, 11.3, 4.0 Hz, 2H), 3.62 (ddd, J = 13.8, 10.5, 3.9 Hz, 2H), 3.57 – 3.46 (m, 9H), 3.39 – 3.33 (m, 1H), 3.30 – 3.27 (m, 1H), 2.14 (t, J = 7.6 Hz, 2H), 2.01 (s, 3H), 1.98 (s, 3H), 1.76 (p, J = 7.4 Hz, 2H), 1.66 – 1.50

(m, 3H), 1.46 – 1.42 (m, 2H), 1.38 – 1.19 (m, 34H), 0.84 (t, $J = 6.7$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, $\text{CD}_3\text{OD}:\text{CDCl}_3$, 1:1): δ 175.2, 174.3, 174.3, 146.0, 145.1, 138.1, 134.8, 130.1, 105.6, 104.5, 104.3, 103.6, 102.8, 98.9, 84.0, 80.0, 76.0, 76.0, 75.8, 75.6, 75.2, 74.7, 74.0, 73.2, 72.9, 72.5, 70.3, 69.2, 69.1, 68.9, 62.3, 62.3, 61.1, 60.4, 54.2, 53.8, 53.7, 53.2, 36.9, 32.9, 32.4, 30.2, 30.2, 30.2, 30.1, 30.0, 30.0, 29.9, 29.9, 29.9, 29.8, 29.8, 29.8, 29.8, 27.5, 27.3, 26.4, 23.1, 23.0, 23.0, 14.3. HRMS (ESI-TOF) m/z : $[\text{M} + \text{Na}]^+$ Calcd. for $\text{C}_{63}\text{H}_{105}\text{N}_7\text{O}_{26}\text{Na}$ 1398.7001; Found. 1398.7015.

(2*S*,3*R*,*E*)-2-Octadecanamido-3-(pivaloyloxy)octadec-4-en-1-yl 3,4,6-tri-*O*-acetyl-2-azidoactamino-2-deoxy- β -D-galactopyranosyl-(1 $\rightarrow$ 3)-[3,4,6-tri-*O*-acetyl-2-azidoactamino-2-deoxy- β -D-galactopyranosyl-(1 $\rightarrow$ 4)]-2,6-di-*O*-acetyl- β -D-galactopyranosyl-(1 $\rightarrow$ 4)-2,3,6-tri-*O*-acetyl- β -D-glucopyranoside (36): To a solution of **21** (21 mg, 0.010 mmol) in AcOH/THF (2/3, 2 mL) was added activated Zn (65 mg, 0.99 mmol). After the mixture was stirred at rt for 12 h, it was filtered through a *Celite* pad and the filtrate was concentrated under reduced pressure. The crude product was stripped with dry toluene (3 $\times$ 3 mL) and then dissolved in 1 mL of dry CH_2Cl_2 . To this solution were added azidoacetic acid (9.2 mg, 0.091 mmol), EDC (17.4 mg, 0.091 mmol), DMAP (1.1 mg, 0.009 mmol), and DIPEA (19.3 μL , 0.091 mmol) in 2 mL of dry CH_2Cl_2 at 0 $^\circ\text{C}$. The mixture was stirred at rt overnight and diluted with CH_2Cl_2 . The organic layer was washed with saturated NaHCO_3 solution, water, and brine, and then dried over Na_2SO_4 . The solution was concentrated under vacuum and the residue was purified by silica gel column chromatography to offer **36** (14 mg, 79%) as a white solid. TLC: $R_f = 0.3$ (EtOAc/Hexane 3:2). ^1H NMR (600 MHz, CDCl_3): δ 7.13 (d, $J = 9.2$ Hz, 1H, -NH), 6.58 (d, $J = 8.6$ Hz, 1H, -NH), 5.75 (dt, $J = 14.1, 6.8$ Hz, 1H, =CH-), 5.62 (d, $J = 9.3$ Hz, 1H, -NH), 5.42 (t, $J = 3.0$ Hz, 1H), 5.38 – 5.30 (m, 3H), 5.25 – 5.19 (m, 2H), 5.15 – 5.09 (m, 2H), 4.89 (dd, $J = 9.8, 7.8$ Hz, 1H), 4.83 (ddd, $J = 10.0, 8.0, 4.1$ Hz, 1H), 4.58 (dd, $J = 12.8, 8.4$ Hz, 1H), 4.42 – 4.36 (m, 2H), 4.35 – 4.30 (m, 1H), 4.28 – 4.23 (m, 4H), 4.21 – 4.12 (m, 7H), 4.09 – 3.95 (m, 4H), 3.94 – 3.87 (m, 3H), 3.81 (dd, $J = 15.9, 9.3$ Hz, 1H), 3.73 – 3.67 (m, 1H), 3.63 – 3.59 (m, 2H), 3.56 (ddd, $J = 9.8, 5.2, 2.0$ Hz, 1H), 3.48 (dd, $J = 9.8, 4.4$ Hz, 1H), 2.20 (s, 3H), 2.19 (s, 3H), 2.12 (bs, 5H, - CH_3 and - CH_2CO -), 2.10 (s, 3H), 2.07 (s, 3H), 2.06 (bs, 2 $\times$ 3H), 2.05 (s, 3H), 2.03 (s, 3H), 2.02 (s, 3H), 2.01 (s, 3H), 1.59 – 1.53 (m, 2H), 1.32 – 1.22 (m, 52H), 1.16 (s, 9H), 0.88 (t, $J = 7.0$ Hz, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3): δ 177.0, 172.6, 170.9, 170.9, 170.7, 170.6, 170.4, 170.2, 169.9, 169.8, 169.3, 168.5, 168.2, 137.2, 124.9, 102.3, 100.9, 100.0, 99.8, 79.2, 74.5, 73.1, 73.0, 72.1, 71.8, 71.5, 71.2, 70.7, 68.4, 68.3,

67.7, 66.7, 66.5, 63.2, 62.2, 61.6, 60.9, 56.1, 52.8, 51.9, 50.4, 38.9, 37.0, 32.4, 32.0, 29.8, 29.8, 29.8, 29.6, 29.6, 29.5, 29.5, 29.3, 29.1, 27.1, 25.8, 22.8, 20.9, 20.9, 20.9, 20.8, 20.8, 20.8, 20.8, 20.7, 20.7, 20.7, 20.6, 14.2. HRMS (ESI-TOF) m/z : $[M + H]^+$ Calcd. for $C_{91}H_{148}N_9O_{35}$ 1925.9948; Found 1925.9997.

(2*S*,3*R*,*E*)-2-Octadecanamido-3-hydroxyoctadec-4-en-1-yl 2-azidoactamino-2-deoxy- β -D-galactopyranosyl-(1 $\rightarrow$ 3)-[2-azidoactamino-2-deoxy- β -D-galactopyranosyl-(1 $\rightarrow$ 4)]- β -D-galactopyranosyl-(1 $\rightarrow$ 4)- β -D-glucopyranoside (37): Compound **36** (6.8 mg, 68%, a white glassy solid) was prepared from **37** (14 mg, 0.007 mmol) by the same procedure and reaction conditions employed for the synthesis of **6a**. TLC: R_f = 0.3 ($CHCl_3$ /MeOH 1:1). 1H NMR (600 MHz, $CD_3OD:CDCl_3$, 3:2): δ 5.70 – 5.62 (m, 1H), 5.42 (dd, J = 15.2, 7.9 Hz, 1H), 4.90 (d, J = 8.6 Hz, 1H, anomeric), 4.56 (d, J = 8.2 Hz, 1H, anomeric), 4.33 – 4.22 (m, 4H), 4.19 (dd, J = 10.0, 3.5 Hz, 1H), 4.09 – 4.00 (m, 2H), 4.00 – 3.89 (m, 4H), 3.90 – 3.75 (m, 7H), 3.75 – 3.60 (m, 7H), 3.57 – 3.47 (m, 7H), 3.37 – 3.33 (m, 1H), 2.14 (t, J = 7.6 Hz, 2H), 2.06 – 1.95 (m, 2H), 1.65 – 1.49 (m, 3H), 1.37 – 1.20 (m, 49H), 0.86 (t, J = 7.0 Hz, 6H). $^{13}C\{^1H\}$ NMR (150 MHz, CD_3OD): δ 174.8, 174.6, 134.2, 129.3, 103.6, 103.5, 102.9, 101.8, 83.3, 79.0, 75.2, 74.98, 74.5, 73.9, 73.3, 71.7, 71.5, 71.3, 69.6, 68.5, 61.5, 60.4, 59.9, 58.8, 53.1, 51.8, 36.2, 32.2, 31.7, 29.5, 29.3, 29.2, 26.9, 25.8, 22.4, 13.5. HRMS (ESI-TOF) m/z : $[M - H]^-$ Calcd. for $C_{64}H_{114}N_9O_{23}$ 1376.8022; Found 1376.8009.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at https://pubs.acs.org/****

1D and 2D NMR spectra of all new compounds.

AUTHOR INFORMATION

Corresponding Author

Zhongwu Guo – Department of Chemistry, University of Florida, 214 Leigh Hall, Gainesville, Florida 32611, United States; orcid.org/0000-0001-5302-6456; Email: zguo@chem.ufl.edu

Authors

Rajendra S. Rohokale – Department of Chemistry, University of Florida, 214 Leigh Hall,
Gainesville, Florida 32611, United States

Qingjiang Li – Department of Chemistry, University of Florida, 214 Leigh Hall, Gainesville,
Florida 32611, United States

Complete contact information is available at: https://pubs.acs.org/***

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

The authors thank NSF for a grant (CHE-1800279) to support this research.

References

1. Lahiri, S.; Futerman, A. H., The metabolism and function of sphingolipids and glycosphingolipids. *Cell. Mol. Life Sci.* **2007**, *64*, 2270-2284.
2. Todeschini, A. R.; Hakomori, S. I., Functional role of glycosphingolipids and gangliosides in control of cell adhesion, motility, and growth, through glycosynaptic microdomains. *Biochim. Biophys. Acta* **2008**, *1780*, 421-433.
3. Wennekes, T.; van den Berg, R. J.; Boot, R. G.; van der Marel, G. A.; Overkleeft, H. S.; Aerts, J. M., Glycosphingolipids - nature, function, and pharmacological modulation. *Angew. Chem. Int. Ed.* **2009**, *48*, 8848-8869.
4. Kolter, T., Ganglioside biochemistry. *ISRN Biochem.* **2012**, *2012*, 506160.
5. D'Angelo, G.; Capasso, S.; Sticco, L.; Russo, D., Glycosphingolipids: synthesis and functions. *FEBS J.* **2013**, *280*, 6338-6353.
6. Thompson, T. E.; Tillack, T. W., Organization of glycosphingolipids in bilayers and plasma membranes of mammalian cells. *Annu. Rev. Biophys. Biophys. Chem.* **1985**, *14*, 361-386.
7. Iwabuchi, K.; Nakayama, H.; Masuda, H.; Kina, K.; Ogawa, H.; Takamori, K., Membrane microdomains in immunity: Glycosphingolipid-enriched domain-mediated innate immune responses. *Biofactors* **2012**, *38*, 275-283.
8. Tettamanti, G.; Bassi, R.; Viani, P.; Riboni, L., Salvage pathways in glycosphingolipid metabolism. *Biochimie* **2003**, *85*, 423-437.
9. Varki, A., Biological roles of oligosaccharides: All of the theories are correct. *Glycobiology* **1993**, *3*, 97-130.
10. Hakomori, S. I., Cell adhesion/recognition and signal transduction through glycosphingolipid microdomain. *Glycoconj. J.* **2000**, *17*, 143-151.

11. Schengrund, C.-L., Gangliosides: Glycosphingolipids essential for normal neural development and function. *Trend. Biochem. Sci.* **2015**, *40*, 397-406.
12. Zheng, C.; Terreni, M.; Sollogoub, M.; Zhang, Y., Ganglioside GM3 and its role in cancer. *Curr. Med. Chem.* **2019**, *26*, 2933-2947.
13. Groux-Degroote, S.; Guérardel, Y.; Delannoy, P., Gangliosides: Structures, biosynthesis, analysis, and roles in cancer. *Chembiochem* **2017**, *18*, 1146-1154.
14. Qamsari, E. S.; Nourazarian, A.; Bagheri, S.; Motallebnezhad, M., Ganglioside as a therapy target in various types of cancer. *Asian Pac. J. Cancer Prev.* **2016**, *17*, 1643-1647.
15. Inokuchi, J., GM3 and diabetes. *Glycoconj. J.* **2014**, *31*, 193-197.
16. van Echten-Deckert, G.; Walter, J., Sphingolipids: Critical players in Alzheimer's disease. *Prog. Lipid Res.* **2012**, *51*, 378-393.
17. Ariga, T.; Wakade, C.; Yu, R. K., The pathological roles of ganglioside metabolism in Alzheimer's disease: effects of gangliosides on neurogenesis. *Int. J. Alzheimers Dis.* **2011**, *2011*, 193618.
18. Kaida, K.; Ariga, T.; Yu, R. K., Antiganglioside antibodies and their pathophysiological effects on Guillain-Barré syndrome and related disorders - a review. *Glycobiology* **2009**, *19*, 676-692.
19. Kavaliauskiene, S.; Lingelem, A. B. D.; Skotland, T.; Sandvig, K., Protection against Shiga Toxins. *Toxins* **2017**, *9*, 44.
20. Smith, D. C.; Lord, J. M.; Roberts, L. M.; Johannes, L., Glycosphingolipids as toxin receptors. *Semin. Cell Dev. Biol.* **2004**, *15*, 397-408.
21. Viard, M.; Parolini, I.; Rawat, S. S.; Fecchi, K.; Sargiacomo, M.; Puri, A.; Blumenthal, R., The role of glycosphingolipids in HIV signaling, entry and pathogenesis. *Glycoconj. J.* **2004**, *20*, 213-222.
22. Hunter, C. D.; Guo, T.; Daskhan, G.; Richards, M. R.; Cairo, C. W., Synthetic strategies for modified glycosphingolipids and their design as probes. *Chem. Rev.* **2018**, *118*, 8188-8241.
23. Vankar, Y. D.; Schmidt, R. R., Chemistry of glycosphingolipids-carbohydrate molecules of biological significance. *Chem. Soc. Rev.* **2000**, *29*, 201-216.
24. Gigg, J.; Gigg, R., Synthesis of glycolipids. *Top. Curr. Chem.* **1990**, *154*, 77-139.
25. Imamura, A.; Kiso, M., Chemical synthesis of gangliosides. *Meth. Mol. Biol.* **2018**, *1804*, 293-310.
26. Fujikawa, K.; Nakashima, S.; Konishi, M.; Fuse, T.; Komura, N.; Ando, T.; Ando, H.; Yuki, N.; Ishida, H.; Kiso, M., The first total synthesis of ganglioside GalNAc-GD1a, a target molecule for autoantibodies in Guillain-Barre Syndrome. *Chem. Eur. J.* **2011**, *17*, 5641-5651.
27. Yamamoto, T.; Hasegawa, H.; Hakogi, T.; Katsumura, S., Versatile synthetic method for sphingolipids and functionalized sphingosine derivatives via olefin cross metathesis. *Org. Lett.* **2006**, *8*, 5569-5572.

28. Imamura, A.; Ando, H.; Ishida, H.; Kiso, M., Ganglioside GQ1b: Efficient total synthesis and the expansion to synthetic derivatives to elucidate its biological roles. *J. Org. Chem.* **2009**, *74*, 3009-3023.
29. Fujikawa, K.; Nohara, T.; Imamura, A.; Ando, H.; Ishida, H.; Kiso, M., A cyclic glucosyl ceramide acceptor as a versatile building block for complex ganglioside synthesis. *Tetrahedron Lett.* **2010**, *51*, 1126-1130.
30. Yu, H.; Cheng, J.; Ding, L.; Khedri, Z.; Chen, Y.; Chin, S.; Lau, K.; Tiwari, V. K.; Chen, X., Chemoenzymatic synthesis of GD3 oligosaccharides and other disialyl glycans containing natural and non-natural sialic acids. *J. Am. Chem. Soc.* **2009**, *131*, 18467-18477.
31. Yu, H.; Li, Y.; Zeng, J.; Thon, V.; Nguyen, D. M.; Ly, T.; Kuang, H. Y.; Ngo, A.; Chen, X., Sequential one-pot multienzyme chemoenzymic synthesis of glycosphingolipid glycans. *J. Org. Chem.* **2016**, *81*, 10809-10824.
32. Santra, A.; Li, Y.; Yu, H.; Slack, T. J.; Wang, P. G.; Chen, X., Highly efficient chemoenzymic synthesis and facile purification of α -Gal pentasaccharyl ceramide Gal α 3nLc4 β Cer. *Chem. Commun.* **2017**, *53*, 8280-8283.
33. Yu, H.; Santra, A.; Li, Y.; McArthur John, B.; Ghosh, T.; Yang, X.; Wang Peng, G.; Chen, X., Streamlined chemoenzymatic total synthesis of prioritized ganglioside cancer antigens. *Org. Biomol. Chem.* **2018**, *16*, 4076-4080.
34. Wen, L.; Edmunds, G.; Gibbons, C.; Zhang, J.; Gadi, M. R.; Zhu, H.; Fang, J.; Liu, X.; Kong, Y.; Wang, P. G., Toward automated enzymatic synthesis of oligosaccharides. *Chem. Rev.* **2018**, *118*, 8151-8187.
35. Wang, P. G.; Liu, Y.; Wen, L.; Li, L.; Gadi, M. R.; Guan, W.; Huang, K.; Xiao, Z.; Wei, M.; Ma, C.; Zhang, Q.; Yu, H.; Chen, X.; Fang, J., A general chemoenzymic strategy for the synthesis of glycosphingolipids. *Eur. J. Org. Chem.* **2016**, *2016*, 4315-4320.
36. Gagarinov, I. A.; Li, T.; Torano, J. S.; Caval, T.; Srivastava, A. D.; Kruijtzter, J. A. W.; Heck, A. J. R.; Boons, G.-J., Chemoenzymatic approach for the preparation of asymmetric bi-, tri-, and tetra-antennary N-glycans from a common precursor. *J. Am. Chem. Soc.* **2017**, *139*, 1011-1018.
37. Danby, P. M.; Withers, S. G., Advances in enzymatic glycoside synthesis. *ACS Chem. Biol.* **2016**, *11*, 1784-1794.
38. Schmaltz, R. M.; Hanson, S. R.; Wong, C.-H., Enzymes in the Synthesis of Glycoconjugates. *Chem. Rev.* **2011**, *111*, 4259-4307.
39. Jacques, S.; Rich, J. R.; Ling, C.-C.; Bundle, D. R., Chemo-enzymatic synthesis of GM3 and GM2 gangliosides containing a truncated ceramide functionalized for glycoconjugate synthesis and solid phase applications. *Org. Biomol. Chem.* **2006**, *4*, 142-154.
40. Blixt, O.; Vasiliu, D.; Allin, K.; Jacobsen, N.; Warnock, D.; Razi, N.; Paulson, J. C.; Bernatchez, S.; Gilbert, M.; Wakarchuk, W., Chemoenzymatic synthesis of 2-azidoethyl-

- ganglio-oligosaccharides GD3, GT3, GM2, GD2, GT2, GM1, and GD1a. *Carbohydr. Res.* **2005**, *340*, 1963-1972.
41. Guilbert, B.; Flitsch, S. L., A short chemo-enzymic route to glycosphingolipids using soluble glycosyl transferases. *J. Chem. Soc., Perkin Trans. 1* **1994**, 1181-1186.
 42. Vaughan, M. D.; Johnson, K.; DeFrees, S.; Tang, X.; Warren, R. A.; Withers, S. G., Glycosynthase-mediated synthesis of glycosphingolipids. *J. Am. Chem. Soc.* **2006**, *128*, 6300-6301.
 43. Rich, J. R.; Cunningham, A.-M.; Gilbert, M.; Withers, S. G., Glycosphingolipid synthesis employing a combination of recombinant glycosyltransferases and an endoglycoceramidase glycosynthase. *Chem. Commun.* **2011**, *47*, 10806-10808.
 44. Rich, J. R.; Withers, S. G., A chemoenzymatic total synthesis of the neurogenic starfish ganglioside LLG-3 using an engineered and evolved synthase. *Angew. Chem. Int. Ed.* **2012**, *51*, 8640-8643.
 45. Hancock, S. M.; Rich, J. R.; Caines, M. E. C.; Strynadka, N. C. J.; Withers, S. G., Designer enzymes for glycosphingolipid synthesis by directed evolution. *Nat. Chem. Biol.* **2009**, *5*, 508-514.
 46. Kannagi, R.; Levery, S. B.; Hakomori, S., Hybrid type glycolipids (lacto-ganglio series) with a novel branched structure. Their presence in undifferentiated murine leukemia cells and their dependence on differentiation. *J. Biol. Chem.* **1984**, *259*, 8444-8451.
 47. Shigeta, K.; Ito, Y.; Ogawa, T.; Kirihata, Y.; Hakomori, S.; Kannagi, R., Monoclonal antibodies directed to chemically synthesized lactogangliotetraosylceramide, a leukemia-associated antigen having a novel branching structure. *J. Biol. Chem.* **1987**, *262*, 1358-62.
 48. Ito, Y.; Sugimoto, M.; Sato, S.; Ogawa, T., Synthetic studies on cell surface glycans. 45. Total synthesis of a lacto-ganglio series glycosphingolipid, M1-XGL-1. *Tetrahedron Lett.* **1986**, *27*, 4753-4756.
 49. Nakashima, S.; Ando, H.; Saito, R.; Tamai, H.; Ishida, H.; Kiso, M., Efficiently synthesizing lacto-aanglio-series gangliosides by using a glucosyl ceramide cassette approach: The total synthesis of ganglioside X2. *Chem. Asian J.* **2012**, *7*, 1041-1051.
 50. Nakashima, S.; Ando, H.; Imamura, A.; Yuki, N.; Ishida, H.; Kiso, M., A first total synthesis of a hybrid-type ganglioside associated with amyotrophic lateral sclerosis-like disorder. *Chem. Eur. J.* **2011**, *17*, 588-597.
 51. Kale, R. R.; Clancy, C. M.; Vermillion, R. M.; Johnson, E. A.; Iyer, S. S., Synthesis of soluble multivalent glycoconjugates that target the Hc region of botulinum neurotoxin A. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 2459-2464.
 52. Suihko, M.; Ahlgren, M.; Aulaskari, P.; Rouvinen, J., Improved synthesis and characterization of 1,3,4,6-tetra-O-acetyl-2-(N-acetylacetamido)-2-deoxy- β -D-glucopyranose. *Carbohydr. Res.* **2001**, *334*, 337-341.

53. Wrodnigg, T.; Lundt, I.; Stuetz, A., Synthesis of N-protected galactosamine building blocks from D-tagatose via the Heyns rearrangement. *J. Carbohydr. Chem.* **2006**, *25*, 33-41.
54. Du, W.; Gervay-Hague, J., Efficient synthesis of α -galactosyl ceramide analogues using glycosyl iodide donors. *Org. Lett.* **2005**, *7*, 2063-2065.
55. Meek, S. J.; O'Brien, R. V.; Llaveria, J.; Schrock, R. R.; Hoveyda, A. H., Catalytic Z-selective olefin cross-metathesis for natural product synthesis. *Nature* **2011**, *471*, 461-466.
56. Ogba, O. M.; Warner, N. C.; O'Leary, D. J.; Grubbs, R. H., Recent advances in ruthenium-based olefin metathesis. *Chem. Soc. Rev.* **2018**, *47*, 4510-4544.
57. Zhu, X.; Schmidt, R. R., Selective conversion of N-trichloroethoxycarbonyl (Troc) groups into N-acetyl groups in the presence of N-tert-butoxycarbonyl (Boc) protecting groups. *Synthesis* **2003**, 1262-1266.